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Cancer is extremely challenging to treat as every patient responds differently to 
treatments, depending on the specific molecular aberrations and deregulated signaling 
pathways driving their tumors. To address this heterogeneity and improve patient 
outcomes, therapies targeting specific pathways have been developed. The use of 
computational pathway analysis tools and genomic data can help guide the use of 
targeted therapies by assessing which pathways are deregulated in patient 
subpopulations and individual tumors. However, most pathway analysis tools do not 
account for complex interactions inherent to signaling pathways, and are not capable of 
integrating different types of genomic data (multiomic data). To address these 
limitations, this dissertation focuses on developing user-friendly multiomic gene set 
analysis tools, and utilizing bioinformatics tools to measure pathway activation for 
multiple pathways simultaneously in cancer. 
 Chapter 2 first describes the need for genomics and pathway-based analyses in 
cancer using the commonly aberrant RAS pathway as an example. Chapter 3 utilizes 
pathway-based gene expression signatures and the pathway analysis toolkit ASSIGN to 
interrogate pathways from the growth factor receptor network (GFRN) in breast cancer. 
Two discrete phenotypes, which correlated with mechanisms of apoptosis and drug 
response, were characterized from GFRN activity. These phenotypes have the potential 
to pinpoint more effective breast cancer treatments. Chapter 4 describes the 
development of Gene Set Omic Analysis (GSOA), a novel gene set analysis tool which 
uses machine learning to identify pathway differences between two given biological
 
iv 
conditions from multiomic data. GSOA demonstrated its capacity to identify pathways 
known to play a role in various cancers, and improves upon other methods because of 
its ability to decipher complex multigene and multiomic patterns. Chapter 5 describes 
GSOA-shiny, a novel web application for GSOA, which provides biologists with lack of 
bioinformatics experience access to multiomic gene set analysis from an easy-to-use 
interface. Overall, this dissertation presents novel breast cancer phenotypes with clinical 
implications, provides the research community with gene expression signatures for 
GFRN components, and presents an innovative method and web application for gene  
set analysis–all contributing to furthering the field of personalized oncology. 
This dissertation is dedicated to all the precious lives and loved ones we have lost too 
early to cancer.
…you just work day and night if the cause in your heart is justified.” - Jon Huntsman, Sr. 
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The ultimate goal of oncology is to develop and select the most effective 
treatments for the right patient, at the right time, based on the molecular aberrations and 
oncogenic signaling pathways driving their specific tumors [1]. The emergence of high-
throughput sequencing technologies has revolutionized oncology, more effectively 
personalized medicine, and led to the accumulation of a large volume of genomic data 
[2]. This technology has allowed for the determination of genome sequences and the 
ability to capture the activity of thousands of molecular events simultaneously in order to 
better understand the behavior of tumors [3]. As a result, computational tools for 
pathway analysis have been developed to analyze genomic data from tumors, at the 
pathway level, to provide insight into biological systems and cellular processes, and 
make inferences about pathway activity [4]. This knowledge can be used to determine 
clinically relevant tumor subtypes, predict drug targets, and generate testable 
hypotheses  [5].  
Different pathway analysis approaches exist such as gene ontology methods, 
gene set enrichment analysis, network modeling, and gene expression signatures [6]; 
however, this dissertation focuses on two distinct approaches. One approach is the use 
of gene expression signatures (as surrogates of pathway activation) to probe tumors to 
predict response to targeted therapies. The other is gene set analysis, which aims to 






sets or pathways by utilizing numerous distinct types of genomic data [6]. This 
introductory chapter provides the background information required for understanding the 
motivations for dissecting genomic cancer data at the pathway level, and for 
understanding the data presented in Chapters 2-5. 
 
Cancer: An Overview 
Cancer is a group of over 200 life-threating genetic diseases that cause 
tremendous physical, mental, and financial burdens on patients, their families, and 
society as a whole [7]. In 2012 alone, an estimated 14 million new cases of cancer were 
diagnosed, and approximately 8.2 million cancer-related deaths occurred worldwide. 
Additionally, 39 percent of the world population will be diagnosed with cancer at some 
point in their lifetime [8]. Therefore, there is a strong need to find better cancer 
treatments in order to improve survival rates and support the large number of patients 
suffering from cancer.  
Cancer is caused by the accumulation of genetic aberrations that result in 
uncontrolled cellular growth [9]. Normal functioning cells can regulate growth, division, 
and death (apoptosis) in a tightly controlled manner [10]. In cancer, however, oncogenic 
signaling pathways become deregulated due to mutations in oncogenes or tumor 
suppressors [11]. Many genetic mutations have been discovered in cancer; however, 
mutations tend to converge on a handful of key pathways that regulate vital cellular 
processes such as cell growth, cell survival, and genome maintenance [12,13]. 
Deregulation of these pathways results in sustained proliferative signaling, resistance to 
death signals, and the development of cellular masses called tumors [14]. Benign tumors 
are considered nonmalignant and do not spread. Malignant tumors, conversely, have the 
ability to invade surrounding tissues, metastasize through the blood or lymph system 






Metastatic cancer is difficult to treat and is the leading cause of death in cancer patients 
[15]. Survival rates have improved for some cancer types, such as breast, skin, and 
prostate; however, few improvements have been seen in harder to treat cancers, such 
as  brain, lung, liver, pancreas, and stomach, further highlighting the need to determine 
the molecular underpinning and more effective treatments [16].  
 
The Need for Personalized Oncology 
Cancer is extremely challenging to treat because every patient responds to 
therapies differently depending on the unique genomic aberrations and altered signaling 
pathways that drive their tumors [17]. Every type of cancer and patient tumor, regardless 
of classification, is unique at the genetic, pathological, prognostic, and therapeutic level 
[18]. For example, breast cancer, a solid tumor, is clinically different from leukemia, a 
blood cancer, and can also be categorized into distinct biological subtypes with different 
molecular features and drug response profiles [19]. Cancer cells within the same patient 
tumor can also be subtly or dramatically different [20]. Thus, intertumor and intratumor 
heterogeneity makes selecting optimal treatments challenging and contributes to 
therapeutic failures, drug resistance, and recurrence of disease [21, 22]. To combat 
these issues, oncology has moved towards more personalized medicine approaches 
[23]. 
Personalized medicine, precision medicine, or genomic medicine, are loosely 
used terms that describe medical approaches that utilize genetic or genomic profiles 
from individuals to guide medical decisions in regards to prevention, diagnosis, and 
treatment selection [24]. Identifying specific treatments for individual patients usually 
begins with researchers discovering particular genomic aberrations in patient subgroups, 
and then testing drugs that target those aberrations in cell lines and animal models. If 






those aberrations [2]. Although personalized medicine is becoming a realistic option for 
treating cancer, much work is required before it is considered standard of care.  
Currently, pathological tests such as lymph node (LN) status and histological 
grade can be used to help determine diagnoses and prognoses, and guide drug 
treatments [25–27]. However, due to lack of specificity, patients are often treated using a 
“trial and error process” until an effective treatment is found. Common anticancer 
treatments include tumor removal surgery, chemotherapy (which targets all dividing 
cells), radiation therapy, and more recently, targeted therapies [28]. Chemotherapy and 
radiation are harsh treatments, and physicians devote an enormous amount of time and 
energy treating their side effects [29]. Therefore, much attention has been focused on 
the use of less toxic targeted therapies [23].  
 
Targeted Therapies and Molecular Biomarkers 
Targeted therapies are a class of cancer drugs designed to inhibit specific 
molecular targets that contribute to tumor growth and progression [1]. Targeted 
therapies have contributed to personalized medicine and are an advancement over 
conventional cytotoxic chemotherapies, however they are still often used in combination 
[30–32]. Targeted therapies have a wide range of targets, including proteins involved in 
oncogenic pathways related to cellular growth, division, invasion, DNA damage, 
apoptosis, angiogenesis, and tumor metabolism [9,11]. Many targeted therapies are 
being used in the clinic, being testing in clinical trials, or are under development [33, 34]. 
However, successful use of targeted therapies is highly dependent on the discovery of 
accurate molecular biomarkers to classify patients into treatment subgroups [24]. 
Biomarkers can be measurements of chemical or molecular substances [35].   
Some of the earliest biomarkers for predicting response to targeted therapies 






proteins using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) 
[36]. For example, the expression of the receptors estrogen (ER) or progesterone (PR) 
in breast cancer can be used to recommend hormone therapies, such as Tamoxifen (an 
estrogen receptor inhibitor) [37, 38]. In addition, expression of the receptor HER2 is a 
biomarker for response to the HER2 inhibitor, Herceptin [39, 40]. More recently, due to 
the rise in genomic sequencing technologies, genetic mutations have been used as 
biomarkers for targeted therapies [41].  
A successful example, and a model for other targeted therapies, is the small 
molecule kinase inhibitor Imatinib (Gleevec) in the treatment of chronic myeloid leukemia 
(CML) [32]. CML is driven by the fusion of BCR and ABL, which results in constitutive 
activation of the Abl kinase, and signaling to its downstream oncogenic pathways RAS 
and phosphatidylinositol 3-kinase (PI3K). Imatinib blocks the BCR–ABL kinase, slows 
down cell growth, and increases apoptosis [42]. Response to Imatinib directly correlates 
with the presence of the BCR-ABL gene fusion. Other examples highlighting genetic 
mutations as biomarkers include the use of the epidermal growth factor receptor (EGFR) 
inhibitor, Erlotinib, in lung cancer patients with point mutations in the kinase domain of 
EGFR, and the BRAF inhibitor, Vemurafenib, in melanoma patients harboring BRAF 
mutations [43 ,44].  Therefore, predicting response to targeted therapies relies upon the 
identification of specific genomic biomarkers and illustrates the importance of 
understanding the molecular mechanisms of individual tumors. 
 
Mutations Do Not Always Reflect Pathway Activation 
The use of genetic biomarkers has advanced the use of targeted therapies in 
cancer, but unfortunately, DNA mutations do not always correlate with drug response 
and fail to include the complexity inherent to cancer signaling pathways [45]. Targeted 






activated at various points. Therefore, it is often difficult to tell which, and if, a pathway 
has become activated by looking at single gene mutations [5]. If upstream pathway 
components are not affected by DNA mutations, it cannot be assumed that the pathway 
has not become activated by downstream components.  
For example, the RAS pathway, a commonly activated pathway in many different 
types of cancer such as pancreatic, lung, and colon, can become activated in numerous 
different ways [46]. These include mutations in the RAS gene itself, in upstream growth 
factor receptors such as EGFR or IGF1R, and in downstream pathway components such 
as BRAF or MEK [47, 48]. In addition to up- and downstream DNA mutations, pathways 
can become activated by other neighboring pathways. For example, RAS can become 
activated by the PI3K, PTEN, or MEKK1 pathways [49]. Therefore, looking only at 
mutations in the RAS gene alone would not always identify tumors with RAS activation 
(a detailed review article of the RAS pathway is described in Chapter 2). Therefore, 
there is a need to develop methods capable of identifying which pathways are activated 
in patient tumors in order to help guide the use of targeted therapies.  
 
Gene Expression Signatures to Guide Targeted Therapy Use 
A gene expression signature is a group of genes whose combined expression 
patterns are uniquely characteristic of a biological phenotype [50]. Gene expression 
signatures have been used in cancer for determining diagnoses, forecasting prognosis, 
and predicting response to treatments [51]. Gene expression signatures can also be 
used to identify pathway activation in tumors [52, 53]. Accounting for the expression of 
multiple genes in a pathway as an indicator of pathway activation is more appropriate 
than relying on single genes or proteins, as pathways can become activated by multiple 







One method for creating pathway-based gene expression signatures is by 
experimentally perturbing a pathway of interest in a controlled manner in cells, extracting 
and sequencing the RNA, and generating signatures from the most significantly 
differentially expressed genes. Signatures can then be compared onto other samples to 
estimate pathway activity levels [45, 55–58]. For example, microarray gene expression 
signatures for five key oncogenic pathways (MYC, RAS, E2F3, SRC, and β-catenin), 
were generated by activating proteins in human mammary epithelial cells [57]. These 
signatures were projected into human and mouse cells and were able to successfully 
predict the mutational status of the tumors. The RAS and SRC signatures also predicted 
sensitivity to inhibitors of these pathways in cell lines. A signature for RAS was also 
used, in a different study, to identify EGFR and MEK co-inhibition as an effective 
treatment for RAS-active cell lines in non-small cell lung cancer [45]. These results 
demonstrate the benefits of using gene expression signatures to measure pathway 
activation. 
Although pathway-profiling approaches can help better understand pathway 
dysregulation in tumors for guiding the use of targeted therapies, they often fail to 
consider the interactions occurring between pathways, and assume heterogeneity 
between in vitro (cell lines) samples and in vivo samples (patients). Recently, a novel 
bioinformatics tool, Adaptive Signature Selection and InteGratioN (ASSIGN), was 
developed to address these issues [59]. ASSIGN takes a Bayesian factor analysis 
approach and is capable of measuring pathway activation for multiple pathways, and the 
interactions occurring between them. ASSIGN also adapts pathway signatures 
(generated in vitro) to match specific disease samples (in vivo). This tool was used in 
Chapter 3 to probe growth factor receptor network signaling in breast cancer, and has 






The “Multiomic” Genome 
In addition to genetic and gene expression data, large comprehensive studies, 
such as the Cancer Genome Atlas (TCGA), have generated massive volumes of high-
dimensional data exhibiting that cancer can become deregulated at many different 
“omic” levels [60]. Different omic data types can be used to generate biomarkers, 
including genomic (DNA sequence data and copy number changes), transcriptomic 
(mRNA expression), epigenome (methylation changes), metabolomics (metabolite 
levels), and proteomic (protein). These technologies may collectively be defined as 
“omics”, and when multiple strategies are used in combination, can be referred to as 
“multiomic” [61, 62]. Accounting for multiple types of molecular data concurrently can 
provide more biologically-relevant information than observing one data type in isolation 
[41,60,61,63].  
Nevertheless, there is a major challenge in understanding how data from multiple 
profiling technologies can be integrated together to make meaningful clinical decisions. 
Combining different data types from different platforms is computationally and 
quantitatively challenging, and requires techniques beyond the capability of most 
biologists [64]. Therefore, there is a strong need to develop better tools for analyzing 
multiomic data to a gain a comprehensive viewpoint of pathways deregulated in 
particular cancer populations, and to explore the use of targeted therapies [62, 65].   
 
Computational Gene Set Analysis Tools 
Gene set analysis (GSA) is a widely used computational method for analyzing 
large volumes of genomic data at the pathway level [4]. This method reduces the 
complexity of sorting through long gene lists by grouping genes into smaller gene sets or 
pathways with similar biochemical or cellular functions [6]. Statistical methods are then 






assigned by the researcher) [66]. The output of these methods is a list of pathways, that 
can then be used to guide further research to uncover mechanisms underlying biological 
phenomena, or to predict drug response. 
While over 50 different GSA methods exist, Gene Set Enrichment Analysis 
(GSEA), an approach presented by Subramanian et al. in 2005, continues to be the 
most popular and widely used method, likely due its easy-to-use web interface [66, 67]. 
Most tools differ in terms of the methods they use to compute gene set statistics and 
types of omic data they can handle [68]. GSEA is designed exclusively for gene 
expression data [69]; however, as tumors form multiomic landscapes, some methods 
have been expanded to include DNA methylation [70], ChIP-sequencing [71], and SNP 
data [72], but typically in isolation. Some methods have recently been developed that 
combine distinctive types of molecular data, but most of these methods are limited to a 
few data types, and are not capable of integrating data types into a single model. 
Therefore, generation of multiomic gene set analysis tools is needed for probing 
pathways to better understand pathway differences between patient subgroups in 
cancer.  
 
Gene Sets Analysis for Biologists 
Although gene set analysis methods help understand large datasets at the 
pathway level, their use is limited to a select population of biologists with bioinformatics 
experience. Stand-alone and web-based applications do exist, but they can be 
challenging to use without bioinformatics skills, creating hurdles for biologists [73]. 
Because biologists vastly outnumber bioinformaticians, there is a gap between the 
developers of computational and statistical methods and laboratory scientists. However, 
because no alternative exists for many of these resources, biologists are willing to spend 






to apply the most advanced computational methods without having to learn the 
command line versions. In general, biologists prefer user-friendly software tools with 
graphical interfaces [74]. This is reflected in the citation impact of easy-to-use programs 
as compared to computational-extensive programs, with GSEA being a prime example 
[66]. Therefore, there is a strong need to lower the barriers and develop easy-to-use web 




To address the issues presented above, this dissertation focuses on utilizing and 
developing computational tools for analyzing omic data from tumors, at the pathway-
level, in order to predict response to targeted therapies. Chapter 2, a review article 
published in Seminars in Cell & Developmental Biology, describes the need for cancer 
genomics and gene expression signature-based approaches when probing the RAS 
pathway, one of cancer’s most frequently mutated networks. Chapter 3, a manuscript in 
revision with Genome Medicine, describes a signature approach using the pathway 
analysis toolkit (ASSIGN) to uncover two pathway-based growth factor receptor network 
phenotypes with treatment implications in breast cancer tumor data. Chapter 4, a 
manuscript published in Genome Medicine, takes a gene set analysis approach, and 
describes our novel computational tool, Gene Set Omic Analysis (GSOA), which 
performs gene set analysis using machine learning algorithms and multiple types of 
genomic data. Chapter 5 takes the GSOA algorithm described in Chapter 4, and 
introduces a novel easy-to-use web application, GSOA-Shiny, which allows biologists 
with no bioinformatics experience to run multiomic gene set analyses, making this type 
of analysis easily available to the broader research community. This dissertation is 






the implications and limitations of these findings, and suggests future directions. This 
dissertation contributes to the field of personalized cancer medicine by improving 
methods for analyzing genomic data at the pathway level and discovering novel 
phenotypes with clinical implications in breast cancer.  
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The growth factor receptor network (GFRN) plays a significant role in driving key 
oncogenic processes. However, assessment of global GFRN activity is challenging due 
to complex crosstalk among GFRN components, or pathways, and the inability to study 
complex signaling networks in patient tumors. Here, pathway-specific genomic 
signatures were used to interrogate GFRN activity in breast tumors and the consequent 
phenotypic impact of GRFN activity patterns. Novel pathway signatures were generated 
by overexpressing key genes from GFRN pathways (HER2, IGF1R, AKT1, EGFR, 
KRAS (G12V), RAF1, BAD) in human primary mammary epithelial cells. The pathway 
analysis toolkit, Adaptive Signature Selection and InteGratioN (ASSIGN), was used to 
estimate pathway activity for GFRN components in 1119 breast tumors from the Cancer 
Genome Atlas (TCGA), and across 55 breast cancer cell lines from the Integrative 
Cancer Biology Program (ICBP43). These signatures were investigated for their 
relationship to pro- and anti-apoptotic protein expression and drug response in breast 
cancer cell lines. Application of these signatures to breast tumor gene expression data 
identified two novel discrete phenotypes characterized by concordant, aberrant 
activation of either the HER2, IGF1R, and AKT pathways (“the survival phenotype”) or 
the EGFR, KRAS (G12V), RAF1, and BAD pathways (“the growth phenotype”). These 
phenotypes described a significant amount of the variability in the total expression data 
across breast cancer tumors and characterized distinctive patterns in apoptosis evasion 
and drug response. The growth phenotype expressed lower levels of BIM and higher 
levels of MCL-1 proteins. Further, the growth phenotype was more sensitive to common 
chemotherapies and targeted therapies directed at EGFR and MEK. Alternatively, the 
survival phenotype was more sensitive to drugs inhibiting HER2, PI3K, AKT, and mTOR, 






pattern in GFRN activity represented by two discrete phenotypes. These phenotypes 
correlate to unique mechanisms of apoptosis and drug response, and have the potential 
of pinpointing targetable aberration(s) for more effective breast cancer treatments. 
 
Background 
Breast cancer remains one of the leading causes of cancer-related death in 
women [1]. It is well established that growth factor receptors and their downstream 
signaling pathways contribute to breast cancer proliferation, survival, and metastasis [2, 
3]. Molecular aberrations can occur in various growth factor receptor network (GFRN) 
members, and have been described in breast cancer [4–6]. These findings have paved 
the way for GFRN targeted treatments which are currently approved for use, being 
evaluated in various stages of clinical development, and in clinical trials [7, 8]. Although 
these treatments do hold promise, relatively little data is available on the cooperativity 
and diversity of complicated GFRN signaling in actual breast tumors. Additionally, 
assessing GFRN activity in patient tumors is extremely challenging due to the lack of 
methods capable of measuring signaling events in tumors. Drug selection is often guided 
by expression of protein biomarkers, and drug resistance often develops due to 
compensation by interacting pathways within the GFRN [9, 10]. Therefore, there is a 
strong need to develop better methods for measuring and understanding GFRN 
signaling events in breast tumors in order to deliver the most effective treatment 
regimens and combat drug resistance [2, 9, 11]. 
Growth factor receptors, such as epidermal growth factor receptor 1 (EGFR), 
human epidermal growth factor receptor 2 (HER2), and insulin-like growth factor 1 
receptor (IGF1R), are key regulatory nodes of the GFRN and are often aberrantly 
activated across breast cancer subtypes [6,12,13]. Approximately 15-30% of breast 






by amplification of HER2 [12]. EGFR amplifications occur in 25% of all triple-negative 
breast cancer (TNBC) patients and are often associated with poor outcomes [6, 8, 14]. 
High IGF1R activity occurs in up to 50% of breast tumors, and is seen across all breast 
cancer subtypes [13]. These receptors can activate downstream oncogenic growth 
cascades such as the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein 
kinase (MAPK) pathways, forming a complex, interconnected, and dynamic signaling 
network [2, 8]. Activation of PI3K by growth factor receptors triggers the 
PI3K/AKT/mammalian target of rapamycin (mTOR) pathway leading to cell proliferation, 
metabolic changes, and cell survival [15–17]. In the MAPK pathway, following growth 
factor receptor activation, RAS becomes activated followed by activation of RAF1, MEK, 
and ERK, leading to transcriptional changes that impact cellular proliferation, motility, 
and evasion of apoptosis [6, 8, 18, 19]. Both the PI3K and MAPK pathways contribute to 
tumor progression by disrupting the balance of pro- and anti-apoptotic proteins of the 
BCL-2 protein family in the mitochondrial (also known as intrinsic) pathway of apoptosis 
[20, 21]. Particular GFRN members can upregulate anti-apoptotic proteins such as BCL-
2, BCL-XL, and MCL-1, and downregulate pro-apoptotic proteins such as BAD, BAX, 
and BIM, all of which contribute to apoptosis evasion and resistance to cancer 
treatments in patients [22–29]. ERBB receptor tyrosine kinases, such as EGFR and 
HER2, have a large amount of overlap in the downstream pathways they activate, 
however, individual ERBB receptors have the capability to preferentially bind particular 
downstream signaling molecules [30, 31]. Furthermore, preclinical studies have shown 
that EGFR- and HER2-driven cancers show differential response to targeted therapies. 
EGFR mutant cancers are less responsive to single-agent PI3K/AKT inhibitors in 
comparison to HER2-amplified cancers, and require the inhibition of both the PI3K and 






pathways and invoke nonredundant physiological effects which warrants for specificity 
for the different GFRN components. Therefore, an accurate assessment of global GFRN 
activity is pivotal for selecting targeted treatment strategies that consider the diversity of 
growth and cell survival mechanisms in breast cancer patients. 
Despite the advances in the cellular and molecular characterization of breast 
cancer, effective personalized breast cancer treatment remains elusive. 
Immunohistochemical and gene expression profiling-defined breast cancer molecular 
classification has advanced our understanding of breast cancer prognosis, treatment, 
and improved survival. Currently, breast cancers are stratified into different clinical 
subtypes in order to determine specific treatments, and several breast cancer subtyping 
approaches are currently available. For example, Fluorescence in situ hybridization 
(FISH) or immunohistochemistry (IHC) techniques are often used to determine clinical 
subtypes based on common receptor protein alterations such as estrogen (ER), 
progesterone (PR), and HER2 receptor amplification [7, 33]. Additionally, Ki-67 
(proliferation marker), CK 5/6 (cytokeratin marker), EGFR, androgen receptor (AR), and 
p53 (apoptosis marker) are used as biomarkers to further classify breast cancer using 
IHC methods. Although helpful, IHC methods are often subjected to bias due to tissue 
handling, fixation, antibody sources, and need for physical evaluation by pathologists 
[34, 35]. More recently, Perou and Sorlie et al. proposed five “intrinsic subtypes” that 
have shown utility in guiding therapy by leveraging gene expression data, differences in 
clinical outcomes, and responses to neoadjuvant chemotherapy [7, 14, 36–38]. Further, 
evaluation of gene expression has led to the proposition of several additional subtypes 
including claudin-low, molecular apocrine, and a novel luminal-like subtype [39–44]. 
While molecular subtypes continue to emerge, routine use of such subtypes in clinical 






of the same clinical or intrinsic subtype can show differences in growth, survival, and 
response to therapies [45], and clinical and intrinsic subtypes are sometimes discrepant 
[46]. Approximately one third of HER2+ tumors are not classified as the HER2-enriched 
intrinsic subtype and up to 25% of clinically characterized ER+ tumors are not classified 
as the luminal intrinsic subtype [36]. While IHC methods are single protein based, 
intrinsic subtypes are fundamentally empirical and do not focus on distinct biological 
properties. Thus, both IHC and intrinsic subtypes fail to recapitulate the biological 
heterogeneity within each subtype [47]. Recent studies highlight the discordance 
between the IHC and intrinsic subtypes, which calls for additional work [47, 48]. To 
address these challenges, pathway-level subtyping may provide complementary 
information for determining therapeutic targets. For example, identification of specific 
aberrant pathways within the triple negative and basal-like subtypes may help to explain 
additional heterogeneity and better target these subtypes pharmacologically [49]. Here, 
breast cancer intertumor heterogeneity was explored in terms of GFRN activity for its 
well-known role in growth, evasion of apoptosis, and drug response. 
While biochemical measurement of pathway activity is challenging in human 
tumors due to limited tissue availability and instability of specific proteins, patterns of 
activity across multiple genes—or gene expression signatures—can be used as 
surrogates for pathway activation in tumors and to model biological phenotypes [50–54]. 
Pathway activation has been used to predict drug response to targeted therapies in cell 
lines [52, 54, 55], but to the best of our knowledge, this is the first study which measures 
activity of seven GFRN members concurrently at the pathway level in patient samples. In 
this study, 1119 breast tumors were profiled for GFRN activity across Cancer Genome 
Atlas (TCGA), and across 55 breast cancer cell lines from the Integrative Cancer Biology 






using novel GFRN gene expression signatures for the HER2, IGF1R, AKT, EGFR, 
KRAS (G12V mutation), RAF1, and BAD pathways. These GFRN signatures were 
generated by performing sequencing on RNA collected from primary human mammary 
epithelial cells (HMECs) overexpressing HER2, IGF1R, AKT1, EGFR, KRAS (G12V), 
RAF1, or BAD for 18-36 hours. These signatures capture early transcriptional events 
which occur shortly after oncogene activation, and represent the transcriptional profile of 
pathway activation, and not of a transformed cell. 
Using the pathway analysis toolkit, Adaptive Signature Selection, and 
InteGratioN (ASSIGN), the signatures were projected onto each breast cancer data set 
and uncovered two discrete patterns of GFRN activity [58]. One pattern was 
characterized by concurrent activation of the HER2, IGF1R, and AKT pathways, and 
another was characterized by concurrent activation of the EGFR, KRAS, RAF1, and 
BAD pathways. Typically, when one set of pathways was active, the other set was 
inactive, indicating that each sample tends to have a dominant GFRN phenotype. 
Pathways activation of HER2, IGF1R, and AKT was nicknamed the “survival phenotype” 
and activation of EGFR, KRAS, RAF1, and BAD as the “growth phenotype”. These 
names were chosen for simplicity and based on the known role of AKT signaling in 
cancer cell survival, and the known role of EGFR/RAS signaling in cellular growth [59, 
60]. Importantly, genomic pathway activity corresponded to apoptotic phenotypes. The 
growth phenotype showed upregulation of anti-apoptotic protein, MCL-1 and 
downregulation of pro-apoptotic protein, BIM, as a mechanism of escaping apoptosis. 
Additional subgroups were also identified within each phenotype, including HER2 high 
and HER2 low activity groups within the survival phenotype, and BAD high and BAD low 
activity groups within the growth phenotype. These discrete subgroups displayed 






phenotypes can serve as surrogates for GFRN activity that capture significant variability 
in the gene expression data, differentiate survival mechanisms, and correlate to drug 
response significantly. A major component of the heterogeneity found across tumor 
expression data was contributed by GFRN signaling and was independent of ER, PR, 
and HER2 status compared to intrinsic subtypes. Additionally, a unique aspect is that 
GFRN activity explained the data in a biologically meaningful way. For example, while 
intrinsic subtyping approaches are based on empirical patterns of gene expression and 
do not necessarily represent a biological process, the subgrouping approach represents 
aberrant activity in specific GFRN pathway signaling. Therefore, pathway-based 
phenotypes and subgroups have the potential to complement existing methods and 
identify biologically and clinically relevant patterns in tumors. Taken together, pathway 
signatures not only aid in assessing general pathway activity patterns in a biologically 




Two dominant phenotypes in breast cancer patients and cell lines 
Gene expression signatures were developed and validated for the following 
GFRN pathways: AKT, BAD, EGFR, HER2, IGF1R, KRAS (G12V mutation), and RAF1. 
Signatures were generated by expressing these genes using recombinant adenoviruses 
in normal human mammary epithelial cells (HMECs). The control samples received 
green fluorescent protein (GFP) adenovirus. The overall goal of this approach was to 
capture the downstream transcriptional events specific for each expressed GFRN gene, 
or the gene expression signatures, and to use these signatures to estimate pathway 
activity in cell lines and patient samples. To determine if adenovirus infection led to 






their downstream targets were measured the using Western blots (Supplemental Figure 
3.1). Next, RNA-sequencing (RNA-seq) was performed on multiple replicates of HMECs 
overexpressing GFRN genes and GFP controls. This data was used to generate 
pathway-based gene expression signatures for each overexpressed gene using the 
previously published ASSIGN pathway profiling approach (Supplemental Figures 3.2A-
G) [58]. Briefly, ASSIGN prioritized genes that best discriminated GFP control samples 
from samples overexpressing GFRN genes to generate gene expression signatures. 
Next, ASSIGN was used to estimate the activation of each GFRN member (AKT, BAD, 
EGFR, HER2, IGF1R, KRAS (G12V), and RAF1) in 1119 breast cancer patient samples 
from TCGA and 55 samples from the ICBP panel of breast cancer cell lines. ASSIGN 
was used to measure highly correlated GFRN pathway activity more accurately in 
patient samples with signatures generated in HMECs since ASSIGN estimates 
correlated pathway activities robustly by adapting pathway signatures into specific 
disease context. Robustness of each pathway signature was validated with (1) leave one 
out cross validation (LOOCV), (2) relevant reverse phase protein array (RPPA) scores, 
(3) gene expression data for the overexpressed oncogenes, and (4) mutation data (See 
Methods, Supplemental Figure 3.3, and Supplemental Table 3.1). After validating the 
GFRN signatures, gene set enrichment analysis was performed to identify enriched 
signaling patterns within each signature (refer to “Gene set enrichment analysis on RNA-
Sequencing signatures” in Supplementary Results, Supplemental Tables 3.2-8). 
Finally, unsupervised hierarchical clustering of the pathway activity estimates for 
all GFRN signatures in both ICBP cell lines and TCGA patient data resulted in a 
dichotomous pattern (Figure 3.2A & 3.2B). The HER2, IGF1R and AKT pathways formed 
a cluster, as did the remaining BAD, EGFR, KRAS, and RAF1 pathways (Figures 3.2A & 






and compensation that occurs between the PI3K and MAPK pathways [61]. However, in 
general, when one set of pathways was high, the other set was low, which shows that 
samples expressed a dominant phenotype of GFRN activity. These results strongly 
suggest a pathway-level dichotomization of the GFRN, which is represented by two 
primary growth phenotypes: (1) activation of the HER2/IGF1R/AKT pathways or “survival 
phenotype” (2) activation of the BAD/EGFR/KRAS/RAF1 pathways or “growth 
phenotype.”  
After identifying the two main dichotomous growth phenotypes, these phenotypes 
were investigated for how they related to classic IHC-based subtypes, intrinsic subtypes, 
and additional heterogeneity present within each phenotype (Figure 3.2). To investigate 
if these phenotypes were independent of ER status, pathway activity estimates were 
clustered for ER+ and ER- samples separately for both ICBP and TCGA samples. The 
pathway activity bifurcation pattern, as represented by GFRN phenotypes, was 
consistent within ER+ and ER- samples, indicating GFRN phenotypes are partially 
independent of ER status (Supplemental Figure 3.4). The variability between histological 
and intrinsic subtypes can also been seen in the heatmap sidebars for TCGA and ICBP 
data (Figures 3.2A-D), and in boxplots of pathway activity estimates across clinical and 
intrinsic subtypes in TCGA (Supplemental Figures 3.5 & 3.6). Samples classified as the 
survival phenotype included samples from all histological and intrinsic subtypes 
(Supplemental Tables 3.9-10; Supplemental Figure 3.7). Of the 596 TCGA tumors from 
the survival phenotype, 84.74% were ER+, 72.99% were PR+, 18.12% were HER2+, 
and 26.51%, 17.79%, 6.88%, and 0.34% were of Luminal A, Luminal B, HER2-enriched, 
and Basal subtypes respectively. For the growth phenotype (n=523), even more 
heterogeneity in ER, PR, and HER2 status was observed (ER + 53.54%, ER - 37.67%; 






enriched 3.06%, Luminal A 13.96% and Luminal B 4.02% ). Hence, clinical and intrinsic 
subtypes varied in each phenotype cluster, and the GFRN phenotypes provide additional 
information which complements existing breast cancer clinical and intrinsic subtypes in 
both patient and cell line data [14, 37, 62 ,63]. 
HER2 activity differences were also observed within the survival phenotype, and 
differences in BAD activity within the growth phenotype. To further classify samples 
specifically on these differences, k-means clustering was performed on the AKT, BAD, 
EGFR, and HER2 pathway activity predictions in ICBP and TCGA. The four resulting 
clusters separated the survival phenotype into two subsets of samples that had either 
high or low HER2 activity, and the growth phenotype into two subsets of samples that 
had either high or low BAD activity. These patterns were observed in both the TCGA and 
ICBP datasets (Figures 3.2C & 3.2D). Again, subtype plot against these four subgroups 
as presented in the sidebars reveal there is additional heterogeneity within ER and PR 
status that is captured using GFRN subgroups. Of note, a survival analysis of the four 
subgroups in TCGA did not show significant differences in survival (λ2=5.5, p-
value=0.141, Supplemental Figure 3.8). This indicates that these subgroups may not 
relate to survival directly. Instead, these subgroups discriminate aberrant pathway 
activity that may help select patient subgroups likely to respond to specific drugs 
targeting those pathways. GFRN phenotypes complement ER status and current 
subtyping methods, but are more biologically focused than current intrinsic subtypes and 
are useful in addition to current IHC-based subtypes. 
GFRN phenotypes and subgroups contribute to variances found in  
TCGA breast cancer gene expression data 
In order to determine if the GFRN phenotypes and subgroups contributed to 






principal component analysis was performed on 1119 breast cancer RNA-sequencing 
samples from TCGA. Principal component analysis (PCA) is a dimension reduction 
method capable of identifying uncorrelated sources of variation within a dataset as 
principal components (PCs) [64, 65]. The first five PCs identified in this dataset 
represented the most significant amount of variability, explaining 34.3% of the total 
variance. The remaining components, each accounting for less than 4% of the total 
variation, were not investigated due to their minor contribution to total variance. Of note, 
PC 1 was significantly associated with average gene expression of the samples 
(Spearman’s correlations: -0.786, p-value <0.0001), potentially reflecting technical and 
nondisease-related sample variation (Supplemental Figure 3.9). However, PC 1 was 
included in analyses to demonstrate its performance. To explain variability as presented 
by PC values, currently used histological (ER, PR, and HER2) and intrinsic subtypes 
were compared to GFRN-based approaches. First, each classification approach was 
investigated for if it explained variability in each PC. When comparing PC values, 
significant differences were found between ER+ and ER- samples and PR+ and PR- 
samples for PCs 1 through 5, between HER2+ and HER2- samples for PCs 3, 4, and 5, 
across intrinsic subtypes for PCs 1 through 5 (ANOVA, p-value<0.0001), between 
growth and survival phenotypes for PCs 2 through 5, and across four GFRN subgroups 
for PCs 1 through 5 (ANOVA p-value<0.0001). These results indicated that significant 
variation underlying the TCGA breast cancer data may be contributed from multiple 
sources, including GFRN phenotypes, subgroups, histological and intrinsic subtypes.  
Second, a linear modeling approach was used to model the first five PCs with 
GFRN subgroups, intrinsic subtypes (PAM50), and histological (ER, PR, and HER2) 
subtypes. Variance explained by each model was compared in terms of R2 values. 355 






(R2 = 0.56) and PR (R2 = 0.407) status explained a significant proportion of PC2, but 
explained less than 10% of the total variability in the other PCs. HER2 status alone 
explained less than 4% of the variability for any of the PCs. Both GFRN subgroups and 
intrinsic subtypes explained additional variability in PCs 1-5. For all five PCs, adding the 
GFRN subgroups or intrinsic subtypes to clinical subtypes increased the R2 values of the 
model (p-value < 0.01 for all models tested, Supplemental Figure 3.10 ; Supplemental 
Table 3.11). Specifically, adding GFRN subtypes to a model of PCs explained an 
additional 10-35% (p-value<0.00001) of the variation when compared to a model of ER 
status alone, while PAM50 explained only 4-20% of the variation (Supplemental Table 
3.11).  
On a more granular level, GFRN subgroups explained an additional 13.5% (p-
value<0.00001) of the variability for PC2 which was not explained by ER status alone. 
For PC3, GFRN subtypes explained an additional 35% of the variation when compared 
to a model of ER status alone (ER R2: 0.052, ER + GFRN subtype R2: 0.398, p-value < 
0.00001), and intrinsic subtypes only explained an additional 20% of the variation 
compared to the same model of ER status alone (ER + intrinsic subtype R2: 0.254, p-
value < 0.00001). Overall, the models that contained GFRN subgroups explained a 
larger percentage of the variance of PC 1, PC 3, and PC 4, and models that contained 
intrinsic subgroups explained a larger percentage of the variance of PC 2 and PC 5 ( 
Supplemental Figure 3.10). These significant R2 and p-values confirm the 
nonredundancy of GFRN subgroups in relation to commonly used clinical features in 
breast cancer. Additionally, GFRN subgroups explain additional variance in models of 
PC 1, PC 3, and PC 4 than models containing intrinsic subgroups.  
Next, the variability contributed by GFRN subgroups was investigated in relation 






correlated with the GFRN pathway activation estimates from TCGA (Figure 3.3, 
Supplemental Table 3.12). Again, a striking bifurcated pattern was found in the 
correlations between pathway activity and PCs in this independent variability analysis. 
PC 2 was positively correlated with the EGFR, KRAS, RAF1, and BAD activation, and 
negatively correlated with HER2, IGF1R, and AKT activation. Therefore, PC 2 is 
demonstrating characters of the growth phenotype. PC 3 and PC 4 were positively 
correlated with the HER2, IGF1R, and AKT activation and negatively correlated with the 
EGFR, KRAS, RAF1, and BAD activation, thus representing growth phenotype 
characteristics (Figure 3.3). Both PC 1 and PC5 were negatively correlated with EGFR 
and RAF1 activation, but positively correlated with BAD activation. Since intrinsic 
subtypes are derived empirically without pointing to any specific biological phenomenon, 
a correlation to intrinsic subtypes could not be performed.     
In summary, these novel GFRN subgroups explained a significant amount of 
variability in TCGA RNA-sequencing data. The GFRN subgroups described variation 
beyond ER, PR, and HER2 status in all cases, and beyond intrinsic subtypes for 3 out of 
5 cases. These results suggest that variability in breast cancer data can be further 
explained in terms of the GFRN pathway activity. Therefore, GFRN subgroups can 
augment current breast cancer subtyping methods by encompassing additional 
heterogeneity not captured by traditional approaches. This pathway-based approach 
may further explain specific variation in terms of pathway activity which may point to 
identifying therapeutic targets. 
Breast cancer growth phenotypes bifurcate in expression of  
mitochondrial apoptotic proteins 
Next, differences between the survival and growth phenotypes were examined at 






mechanisms. Although cytotoxic anticancer agents induce cell death through various 
mechanisms, including intrinsic or extrinsic apoptosis, necrosis, autophagy, mitotic 
catastrophe, or senescence [66, 67], we focused on mitochondrial mediated intrinsic 
apoptosis mediated by BCL-2 family proteins for the following reasons. First, BCL-2 
family members, which regulate the commitment to mitochondrial apoptosis by balancing 
pro-apoptotic proteins such as BAD and BIM, and anti-apoptotic proteins such as BCL-2 
or MCL-1 [20], have been shown to contribute to the formation, progression and 
therapeutic response in breast and other cancers [21, 68]. Second, particular GFRN 
signaling pathways, such as those found in the survival and growth phenotypes, have 
the potential to induce apoptosis resistance by dysregulating BCL-2 family proteins, 
suggesting that targeting GFRN members may lead to increased apoptosis [23–29, 69–
71]. Third, several therapeutic strategies targeting anti-apoptotic BCL-2 family members 
are currently under investigation, therefore, understanding which BCL-2 proteins each 
phenotype is expressing may provide insight into additional treatment strategies for 
breast cancer [22, 72–74]. 
Here, Western blotting was used to investigate whether protein expression of 
particular BCL-2 family members differed in breast cancer cell lines classified as the 
survival or growth phenotypes (Figure 3.4). The pro-apoptotic protein BIM and anti-
apoptotic protein MCL-1 were probed across 10 breast cancer cell lines of the survival 
phenotype (8 ER+, 2 ER-), and 10 cell lines of the growth phenotype (10 ER-). Higher 
levels of MCL-1 were found in cell lines of the growth phenotype, and higher levels of 
BIM were found in in the survival phenotype (Figure 3.4B). To determine if differences in 
MCL-1 and BIM protein expression between the survival and growth phenotypes were 
due to other properties, such as ER status, a Western blot assay was performed using 






ER+ cell lines of the growth phenotype, 12 cell lines belonging to the survival phenotype 
(5 novel ER+ cell lines, 3 ER+ repeats from previous assay, and 4 novel ER-) and 7 cell 
lines from the growth phenotype (1 novel ER+ cell line, 2 novel ER-, and 4 ER- repeats) 
were included. The protein expression of MCL-1 and BIM were not strictly dependent on 
the ER status (Supplemental Figure 3.11). 
To understand if similar results could be found in patient tumors, the expression 
of BCL-2 family member genes were examined, and MCL-1 gene expression was found 
to be higher in the growth phenotype of TCGA patient tumors (n=523) versus the 
survival phenotype (n=596, p < 0.0001) (Figure 3.4C). These results were consistent 
with previous studies showing that EGFR signaling can upregulate gene expression of 
MCL-1 [25, 69–71]. In addition to MCL-1 dysregulation, breast cancer cell lines of the 
growth phenotype expressed lower levels of the pro-apoptotic protein BIM (Figure 3.4D). 
In support of this assessment, lower levels of BIM (BCL2L11) gene expression were 
found in ICBP breast cancer cell lines (p = 0.0004) and TCGA tumors (p = 0.0002), and 
RPPA protein expression in TCGA tumors (p < 0.0001) (Figure 3.4D). These results 
concur with literature showing that EGFR signaling through ERK activation can lead to 
repression of BIM [27–29]. Also, the co-occurrence of high MCL-1 levels and low BIM 
levels in the growth phenotype are likely due to MCL-1’s known ability to bind and 
neutralize BIM, which leads to prevention of apoptosis death effector activation [21, 75]. 
In summary, these results show an interesting mitochondrial apoptotic pathway induction 
that is dependent on GFRN activity. Specifically, breast tumors classified as the growth 
phenotype may overexpress MCL-1 and inhibit BIM expression to achieve cell survival. 
These findings illustrate that breast cancer phenotypes, defined by activation of specific 







Growth factor receptor networks predict drug response in 
breast cancer 
Since there was a clear dichotomy in the GFRN signaling mechanisms between 
the survival and growth phenotypes, these phenotypes were investigated for their 
relation to drug response in breast cancer cell lines. Pathway activation estimates were 
correlated with drug response data for 90 drugs from the ICBP breast cancer cell line 
panel. Importantly, a consistent bifurcation pattern was observed for drug response in 
the cell line data that matched the observed pathway-level bifurcation. Specifically, 
cancer cells classified as expressing the survival phenotype were sensitive to therapies 
that target AKT, PI3K, HER2, and mTOR (Figure 3.5A). Additionally, these cell lines 
were more resistant to chemotherapies and targeted therapies that block EGFR and 
MEK. In contrast, cancer cells expressing the growth phenotype were sensitive to 
chemotherapeutics such as docetaxel, paclitaxel, and cisplatin. These cell lines were 
also sensitive to EGFR and MEK targeted therapies, but more resistant to AKT, PI3K, 
HER2, and mTOR inhibitors (Figure 3.5A).  
This dichotomy in drug response of the survival and growth phenotypes was 
further tested in an independent drug response assay. Eight drugs on a panel of 23 
breast cancer cell lines were tested and cell viability was tested upon drug treatment by 
measuring ATP levels. Drugs included were: obatoclax (BCL-2, BCL-XL, BCL-W, BAK 
inhibitor), UMI-77 (selective MCL-1 inhibitor), erlotinib (EGFR inhibitor), doxorubicin 
(topoisomerase II inhibitor), trametinib (MEK inhibitor), neratinib (pan-HER tyrosine 
kinase inhibitor), Sigma-Aldrich AKT1/2 inhibitor (dual AKT1/2 inhibitor), and bafilomycin 
(apoptosis inducer that inhibits PI3K/AKT signaling and autophagy inhibitor) at different 
doses. Again, a discrete pattern was observed between the survival and growth 






Responses to the chemotherapy (doxorubicin) and the EGFR pathway inhibitor 
(erlotinib) were high for the growth phenotype. In contrast, cancer cell lines classified as 
the survival phenotype responded well to drugs targeting components of the PI3K 
pathway, such as Sigma AKT1/2 inhibitor, neratinib, and bafilomycin. 
In addition to the bifurcation of GFRN and drug response, breast tumor cells of 
the growth phenotype showed a higher response to the specific MCL-1 inhibitor, UMI-77 
(Figure 3.5B). This is consistent with the findings that samples within the growth 
phenotype have higher MCL-1 expression than the survival phenotype. Response to 
obatoclax could not be clearly distinguished based on these phenotypes, likely due to its 
nonspecific binding to prosurvival proteins including BCL-2, BCL-XL and MCL-1 [76]. 
Overall, the GFRN phenotype-based drug response predictions were validated in this 
independent drug response assay. Additionally, drug sensitivity of emerging therapies 
such as UMI-77, neratinib, and bafilomycin showed differences between the two 
phenotypes, further highlighting the close relationship between GFRN signaling activity 
and response to therapies directed at pathways in this network. 
When GFRN phenotype subgroups were considered, several drugs in the ICBP 
drug response assay showed significantly different drug response profiles in the 
subgroups found in each GFRN phenotypic arm. For example, PI3K and mTOR inhibitor 
GSK1059615 and HER2/EGFR-targeting drug Lapatinib were more effective in cell lines 
within the survival phenotype showing higher HER2 activity (p = 0.009 and p < 
0.000001, respectively) (Figures 3.6A & 3.6B). Additionally, ICBP cell lines expressing 
the growth phenotype responded better to EGFR targeting drugs AG1478 and gefitinib in 
the EGFR/BAD low cluster when compared to the EGFR/BAD high cluster (p = 0.001 
and p = 0.001, respectively) (Figures 3.6C & 3.6D). 






subtyping approaches, the correlations between pathway activation and drug response 
for ER+ and ER- and HER+ and HER- ICBP cell lines were clustered separately. Again, 
cell lines with high AKT/IGF1R/HER activity, i.e., survival phenotype, were more 
sensitive to HER2/AKT/PI3K targeted drugs even within ER- and HER- cell lines 
(Supplemental Figure 3.12). In ER+ and HER+ cell lines, many PI3K/AKT/HER2-
targeting drugs are more effective in the survival phenotype, as expected. However, 
there was additional drug response heterogeneity within ER+ samples, which is 
associated with variations in BAD and HER2 pathway activity. These subgroups are thus 
helpful to further classify samples for better drug response prediction. To assess drug 
response across ER, PR, and HER2 status, and intrinsic subtypes, it was found that out 
of 90 drugs studied in ICBP only 13 (14.4%), 12 (13.3%), and 19 (21.1%) showed 
significant differences in drug response based on ER, PR, and HER2 status 
respectively, but growth/survival phenotypes were significant for 27 (49%) 
(Supplemental Table 3.13). As further evidence, while HER2 positive status is a 
biomarker for effective HER2 targeted therapy, drug sensitivity does not solely depend 
on HER2 status. For example, while HER2 status performs much better in differentiating 
Lapatinib’s response than ER and PR status (p-value<0.0001 ), some HER2 negative 
cell lines such as HCC70 and 184A1 may respond to Lapatinib (Supplemental Figure 
3.13A-C). The subgroup analysis showed the survival/HER2 high subgroup to be more 
sensitive to Lapatinib than any other subgroup (Figure 3.6B). In contrast, intrinsic 
subgroup analysis showed, in general, that the Luminal subtype was more sensitive, but 
significant variability in Lapatinib sensitivity exists within the Luminal subtype 
(Supplemental Figure 3.13D). Other detailed examples describing comparisons between 
the GFRN phenotypes and other methods are included in Figure 3.6. In conclusion, the 






phenotypes and subgroups could be used to further stratify samples and may help select 
more appropriate candidates for effective drug response. 
 
Discussion 
Targeted therapies directed against the key members of the growth factor 
receptor network (GFRN), such as EGFR, PI3K, AKT, and mTOR inhibitors, are 
currently in preclinical development, clinical trials, or approved for use in breast cancer 
[16]. However, predicting patients’ responses to therapies is challenging due to 
difficulties in measuring complex signaling events in tumors. Here, this issue was 
addressed by investigating global GFRN activity in breast cancer using these novel 
signatures. Two discrete patterns of GFRN pathway activity, or phenotypes, were found 
(Figure 3.7). The “survival phenotype” was characterized by the activation of the HER2, 
AKT, and IGF1R pathways, and the “growth phenotype” as the activation of the EGFR, 
KRAS, RAF1, and BAD pathways. Additional subgroups were also found within the 
survival and growth phenotypes including HER2 high and low activity groups within the 
survival phenotype, and BAD high and low activity groups within the growth phenotype. 
Although these discrete phenotypes were named the “survival” and “growth” phenotypes 
for simplicity, GFRN pathways comprising both groups can contribute to growth and 
survival. To the best of our knowledge, this is the first study to characterize GFRN 
activity using signature-based representations of activity across multiple pathways. 
These discrete subgroups displayed differences in response to targeted- and 
chemotherapies in breast cancer cell lines. For example, conventional chemotherapies 
such as docetaxel, paclitaxel, and doxorubicin were more effective for the growth 
phenotype than the survival phenotype. Sensitivity to PI3K, HER2, AKT, and mTOR 
inhibitors and resistance to conventional chemotherapies was also found in the survival 






hypersensitive to lapatinib, a HER2 and EGFR dual inhibitor. Similarly, the survival 
phenotype/high HER2 subgroup was more sensitive to GSK1059615, a PI3K/mTOR 
inhibitor than the survival phenotype/low HER2 subgroup. Cell lines of the growth 
phenotype responded better to EGFR and MEK inhibitors, and to conventional 
chemotherapies. The growth phenotype/low BAD subtype was more sensitive to both 
AG1478 and gefitinib (EGFR inhibitors) than the growth phenotype/high BAD subtype. 
Overall, the GFRN pathway-based phenotyping contributed to information related to 
drug response. 
Analysis of these novel phenotypes in breast cancer cell lines and tumors also 
revealed differences in intrinsic apoptosis. For example, breast cancer cell lines and 
tumors of the growth phenotype had higher levels of the anti-apoptotic protein MCL-1, 
and lower levels of the critical pro-apoptotic protein BIM. These results are consistent 
with the notion that the MAPK pathway can activate MCL-1 expression and that 
activation of ERK1/2 and the MAPK pathway can repress BIM [25, 27–29]. An 
independent drug assay also showed that the growth phenotypic cell lines responded 
better to an MCL-1 inhibitor (UMI-77). These results suggest that the patients with 
growth phenotypic expression may benefit from treatments that increase BIM, i.e., MCL-
1 inhibitors, in combination with chemotherapies, EGFR inhibitors, or other inhibitors of 
the MAPK pathway [77, 78]. Therefore, targeting GFRN members may be an effective 
therapeutic strategy for inhibiting GFRN pathways and increasing apoptosis [22]. These 
results highlight that mapping phenotypes, such as growth networks in breast tumors, 
can be exploited to guide the use of targeted therapies. This study was limited to how 
GFRN activity related to drug response and cellular intrinsic apoptosis, but it is 
understood that this is not the sole mechanism by which cancer cells die, and other cell 






should also be considered. In addition, as the use of cell lines is limited, a larger-scale 
analysis of apoptotic pathways dysregulation in patient tumor cells of all subtypes will be 
informative in further detailing how these pathways signal in cancer. These phenotypes 
many correlate with other subtyping properties, and may also be confounded by 
properties of intrinsic subtyping.  
Importantly, these newly discovered breast cancer survival and growth 
phenotypes are biologically relevant and offer a direct method for probing and targeting 
the GFRN in breast tumors. In addition, these phenotypes complement widely used 
clinical and intrinsic subtypes, and stratification of cancers by these phenotypes leads to 
better enhanced drug response predictions than classifying cancers by clinical subtyping 
approaches. This is most likely because oncogenic pathway activation was measured 
more comprehensively than relying on single protein measurements. In addition, this 
approach considers crosstalk between members of the GFRN, and correlates with 
biological processes such as cell survival. This pathway-based approach for identifying 
phenotypes allows for exploration of additional heterogeneity occurring within the 
identified phenotypes, which can further improve the ability to stratify breast cancers by 
pathway activity, which then can be used to predict drug response. Although this method 
has added to current approaches for predicting drug response in breast cancer, most 
experiments were performed in breast cancer cell lines with particular classes of drugs; 
additional drug testing should be performed in breast cancer patient cells in order to 
confirm these phenotypes. 
In summary, a novel genomic pathway-based approach of characterizing the 
interactive GFRN activation in breast cancer was used to discover two discrete GFRN 
phenotypes with significant differences in cell survival mechanisms and drug response in 






expression, the GFRN pathway activity, mitochondrial apoptotic network protein 
expression, and drug response (Figure 3.7). While ER, PR, HER2 status, and more 
recently, intrinsic subtype are used to guide breast cancer treatment, these subtyping or 
classifying approaches may not describe signaling pathway dysregulation in tumor cells. 
Pathway activity data provides additional information about tumor cells that can be 
leveraged to predict drug response. Characterizing individual tumors into these 
phenotypes can help determine which patients will benefit from a treatment and select 
the appropriate subpopulations for clinical trials. Importantly, these seven pathways did 
not capture all the heterogeneity of the samples and inclusion of other pathways may 
have additional benefits. Although feasible, additional investigation is needed before 
these phenotypes can be used in clinical trials for patient selection, including the testing 
of these phenotypes in patient primary tumor cells.  
 
Conclusion 
A discriminating bifurcation pattern of key GFRN pathways was identified in 
breast tumors that expands beyond histological and clinical subtypes. These phenotypes 
correlated with unique apoptotic and drug response mechanisms. The ability to measure 
signaling events more accurately in patient tumors advances understandings of the 
biological basis of cancer. These results may lead to more effective and individualized 
treatment selection in patients with breast cancer. 
 
Methods 
Overexpression of genes of interest in human mammary epithelial cells 
In order to create gene expression signatures representative of pathway 
activation, GFRN oncogenes were overexpressed in primary human mammary epithelial 






University of Utah were isolated and cultured according to previously published protocols 
[79]. Cells were grown in serum-free mammary epithelial basal medium (MEBM) plus the 
addition of a “bullet kit” (Lonza) and supplemented with 5 mg/ml transferrin and 10-5 M 
isoproterenol at 5% CO2. Cells were brought to quiescence by growth in low serum 
conditions (0.25% MEBM + “bullet kit”, no EGF) for 36 hours. Cells were infected with 
recombinant adenovirus (at 500 MOI) expressing either human oncogenes AKT1, 
IGF1R, BAD, HER2, KRAS (G12V), RAF1, or GFP control. Cells were incubated with 
virus for 18 hours except for KRAS (G12V), which was incubated for 36 hours. The 
adenoviral expression systems invokes transient gene expression changes which allow 
us to capture the early transcriptional events of each oncogene, as opposed to the 
transcriptional profile of a transformed cell. Recombinant adenoviruses were amplified 
and concentrations were determined using previously published protocols [80]. All 
viruses were obtained from Vector Biolabs, except RAF1 (Cell Biolabs) and EGFR (gift 
from Duke University). 
Western blot analysis for expression of growth factor proteins  
in HMECs and apoptotic proteins in breast cancer cell lines 
Protein from HMECs was extracted from the following breast cancer cell lines: 
HCC3153, HCC1395, ZR75B, HCC1569, HCC2218, SKBR3, LY2, SUM52PE, ZR7530, 
MDAMB361, AU565, BT474, BT483, CAMA1, HCC1419, HCC1428, MCF7, 
MDAMB175, T47D, ZR751, HCC1954, JIMT1, BT549, HCC1143, HCC1806, HCC1937, 
HCC38, HCC70, HS578T, and MDAMB213. To collect protein, cells were washed with 
PBS, scraped on ice into PBS, pelleted by centrifugation, lysed in lysis buffer for 15 
minutes (50 mM Tris (pH 8.0), 140 mM NaCl, 5 mM EDTA, 1% TritionX-100, 0.1% SDS, 
protease cocktail (Sigma), phosphatase inhibitors cocktails 2 and 3 (Sigma), and 






using a BCA assay (Pierce). Electrophoresis was performed on a 8-12% Tris-HCl 
polyacrylamide gel (BioRad) for HMEC western blots, and 18% Criterion TGX 
Tris/Glycine gels (BioRad) for apoptotic proteins. Proteins were then transferred to a 
PVDF membrane using the iBlot® 2 Dry Blotting System (Thermo Fisher Scientific). 
Membranes were blocked for 1 hour with SuperBlock™ (Thermo Fisher Scientific) and 
probed with the following primary antibodies: AKT (#9272), pAKT (#13038), BAD 
(#9292), EGFR (#4267), pEGFR (#2234), HER2 (#2165), pHER2 (#2244), IGF1R 
(#3027), pIGF1R (#3021), KRAS (sc-30), pMEK (#9154), p-cRAF (#9427), GAPDH 
(#5174), and β-tubulin (#2146). Of note, pAKT ran higher than expected due to AKT 
myristoylation. Breast cancer cell line lysates were probed with the following: MCL-1 
(#5453), BIM (#2933), and B-actin (#3700). All antibodies were obtained from Cell 
Signaling Technology, besides KRAS, which was obtained from Santa Cruz. 
Dose response assay 
Cell lines were plated at 2000 cells per well in 384 well plates for 24 hours at 
37°C. All cell lines were obtained from American Type Culture Collection (ATCC). Drugs 
were diluted to six doses in media containing 5% FBS (Gibco/Life technologies) and 1% 
anti–anti (Gibco/Life technologies). Erlotinib, trametinib, UMI-77, obatoclax, doxorubicin, 
and neratinib were purchased from Selleckchem and Bafilomycin and AKT1/2 inhibitor 
were from Sigma-Aldrich. Drugs were dissolved in 100% DMSO and stored at −80°C. 
Cell viability and growth were measured using CellTiter-Glo (Promega) 72 hours after 
treatment. All treatment doses were performed in four replicates. The Drug Discovery 
Core Facility, a part of the Health Sciences Cores at the University of Utah, performed 
the dose response assay. EC50s (concentration of each drug that provides half of the 
maximum response) were determined, and converted the EC50s to drug sensitivity 






calculated from dose response data by plotting in GraphPad Prism 4 and using the 
equation Y = 1/(1 + 10ˆ((logEC50 − X) HillSlope)) with a variable slope (Ymin = 0 and 
Ymax = 1). 
RNA preparation and RNA sequencing 
After transfection with adenovirus and Western blot validation, cells were 
pelleted, washed in PBS, and stored in RNAlater (Ambion). Cells were then DNase 
treated, and RNA was extracted using the RNeasy kit (Qiagen). RNA replicates were 
generated for each overexpressed gene: 6 each for AKT, BAD, IGF1R, and RAF1; 5 for 
HER2; and 12 for GFP control (Gene Expression Omnibus (GEO) accession 
GSE83083). Additionally, 9 replicates of each of KRAS and GFP control were generated 
(GEO accession GSE83083). The EGFR signature and its corresponding GFP control 
were previously generated with 6 replicates of each (GEO accession GSE59765). RNA 
concentration was determined with a Nanodrop (ND-1000). cDNA libraries were 
prepared from extracted RNA using the Illumina Stranded TruSeq protocol (Illumina). 
cDNA libraries were sequenced at Oregon Health and Sciences University using the 
Illumina HiSeq 2000 sequencing platform with six samples per lane. Single-end reads of 
101 base pairs were generated. 
Gene expression data processing, normalization, and datasets 
 The Rsubread R package (Version 1.14.2) was used to align and summarize 
RNA-seq reads to the UCSC hg19 reference genome and annotations [81, 82]. All RNA-
seq data in this study, including HMEC overexpression data (GSE83083, GSE59765), 
TCGA breast cancer data (GSE62944), and ICBP breast cancer RNA-Seq dataset 
(GSE48213), were processed and normalized using a pipeline that can be found at 






Generation of gene expression signatures 
Adaptive Signature Selection and InteGratioN (ASSIGN; Version 1.9.1), a semi-
supervised pathway profiling toolkit, was used to generate gene expression signatures. 
A formal definition of the ASSIGN model and software implementation was previously 
described [58]. RNA-Seq data from HMECs overexpressing GFP control were compared 
to HMECs overexpressing AKT1, IGF1R, BAD, HER2, KRAS (G12V), RAF1, and EGFR. 
ASSIGN uses a Bayesian variable approach to select genes with the highest weights 
and signal strengths, indicating differential expression. These genes represent 
oncogenic signatures. 
Gene set enrichment analysis on RNA-Sequencing signatures 
The R package, Gene Set Variation Analysis for microarray and RNA-seq data 
(GSVA; Version 1.22.0), a nonparametric, unsupervised method for estimating variation 
of gene set enrichments in gene expression data, was used to perform this gene set 
enrichment analysis [84]. GSVA was downloaded from Bioconductor (3.4). RNA-
Sequencing data from HMECs overexpressing GFP (control), AKT1, IGF1R, BAD, 
HER2, KRAS(G12V), RAF1, and EGFR was used as input for the GSVA algorithm. The 
following gene sets were used and downloaded from the Molecular Signatures Database 
(http://software.broadinstitute.org/gsea/downloads.jsp) [85]; 1320 gene sets from the C2: 
canonical pathways collection (c2.cp.v5.2.symbols.gmt) and 50 gene sets from the 
hallmarks collection (h.all.v5.2.symbols.gmt). The following GSVA parameters were 
used: minimum gene set size = 10, maximum gene set size = 500, verbose = TRUE, 
rnaseq=TRUE, and method = “ssgsea”. GSVA returns a matrix containing enrichment 
scores for each sample and gene. The R package limma (version 3.30.2) [86], was used 
to perform a differential expression analysis between each overexpressed gene samples 






Batch adjustment and estimation of pathway activity in ICBP and 
 TCGA BRCA patient samples 
HMEC oncogenic signatures (training data) were applied to 55 ICBP breast 
cancer cells and 1119 TCGA breast cancer patient gene expression datasets (test data) 
to estimate pathway activation status. To avoid confounding batch effects within and 
between the training and test data, the data was adjusted for batch effects. First, in order 
to visualize batch effects in the data a principal component analysis (PCA) was 
performed on the training (HMEC overexpression RNA-seq) data. The training data was 
sequenced separately in three batches, and significant batch effects were observed. 
Batch effects were adjusted using the “ComBat” function from the R package sva 
(version 3.21.1) [83, 87]. ComBat was run using the reference-batch option, which 
adjusts the data to match an indicated batch. The sequencing batch containing AKT1, 
IGF1R, BAD, HER2, and RAF1 was selected as the reference batch. A model-matrix 
indicating which pathway was associated with each training replicate was also included. 
After the first batch adjustment, PCA was performed on the adjusted training data and 
the test data (ICBP breast cancer cell lines or TCGA breast tumors). Significant batch 
effects were identified between the training and test data and performed a second round 
of ComBat adjustment, using the training data as the reference batch. After the second 
batch adjustment, PCA was performed to confirm the resolution of the batch effect. 
Additionally, background baseline gene expression differences were adjusted between 
oncogenic signatures and test samples (ICBP cell lines and TCGA patient data) using 
ASSIGN’s adaptive background parameter. The variation in magnitude and direction of 
signature-relevant gene expression between oncogenic signatures training samples and 
test samples was adjusted using ASSIGN’s adaptive signature parameter. The model 






ASSIGN settings were used for all other parameters. 
Optimization of single-pathway estimates in ICBP cell line and TCGA  
BRCA patient data 
 To determine the optimum number of genes for each oncogenic signature, 
signatures with gene list lengths from 25 to 500 genes, in 25 gene increments, were 
generated using ASSIGN’s single pathway settings. By default, ASSIGN chooses gene 
lists that contain an equal number of genes that have increased or decreased 
expression with pathway activation. ASSIGN also allows a specific gene to be anchored 
in the signature, making sure that gene is always included in the signature, even if it is 
not chosen during gene selection or if it is removed from the signature after Monte Carlo 
simulation. Anchor genes were chosen based on the oncogene overexpressed in each 
signature. Pathway predictions generated by ASSIGN are represented as values from 
zero to one. Values of zero represent no pathway activity, and values of one represent 
high pathway activity. For all the signatures that passed internal leave-one-out-cross-
validation, pathway estimates were included for further validation in proteomics, 
mutation, and gene expression. To determine optimal signature gene list lengths and 
evaluate the robustness of the generated signatures, pathway activation estimates from 
ICBP and TCGA were correlated with proteins that reflect downstream pathway 
activation from corresponding ICBP and TCGA RPPA data as a measurement of protein 
quantity [88, 89]. Significant correlations were found between pathway activation 
estimates for all GFRN signatures and appropriate downstream pathway proteins [13, 
90–92] (Supplemental Table 3.1). Mutation-based analysis was performed using t-tests 
between patient groups based on mutation status in oncogenic proteins. For example, 
TCGA mutation data was analyzed and higher HER2 pathway activation estimates were 






and lower BAD activation estimates in patients with PI3KCA mutations (Supplemental 
Figures 3.3A & 3.3B). In gene expression data, higher pathway activity for AKT, EGFR, 
IGF1R, and RAF1 in TCGA samples classified as “high” expressing using percentiles 
from the TCGA RNA-seq dataset for their respective genes AKT1, EGFR, IGF1R, and 
RAF1 were found (Supplemental Figures 3.3D-G). Samples with 90th percentile or 
higher expression were considered “high” 10th percentile or lower were considered 
”low”, and 10th to 90th percentile were considered “intermediate” expressing samples for 
AKT1, EGFR and RAF1. For IGF1R validation, samples with 80th percentile or higher 
IGF1R expression were considered “high”, 20 percentile or lower was considered “low”, 
and 20 to 80 percentile expression were considered “intermediate” expressing samples. 
Finally, a pairwise Spearman correlation values and calculated p-values between 
pathway predictions and corresponding TCGA reverse phase protein array (RPPA) data, 
were used to determine which gene numbers gave the best correlations. The HER2 and 
AKT signatures performed better with fewer genes. Therefore, 5-, 10-, 15-, and 20-gene 
signatures for HER2 and AKT were generated. Significant correlations were seen 
between pathway estimates and RPPA protein scores. For example, AKT pathway 
activation estimates were significantly correlated with AKT, PDK1, and phosphorylated-
PDK1 protein levels in both ICBP and TCGA (p-values <0.0001) samples. Due to the 
lack of proteins available to validate the BAD signature, negative correlations between 
BAD pathway estimates and AKT protein based on the knowledge that activation of AKT 
leads to BAD inhibition were used [23]. The optimized gene list was the list that gave the 
best average correlation in the expected direction for the RPPA data correlated with 
each pathway in the TCGA data and was significant both in ICBP and TCGA data, with 







Software implementation of pathway activity prediction with  
generated signatures 
The signatures presented here have been included in the latest version of the 
ASSIGN package (v1.11.3) so that pathway activity prediction can be easily performed 
on other datasets. Because the gene list length can affect the results of ASSIGN 
analysis, the signatures can be used in their original form, or the gene list lengths can be 
optimized based on maximizing correlations between ASSIGN activity predictions and a 
set of variables, such as RPPA data. 
Determination of growth factor phenotypes in ICBP and TCGA 
Cell lines from ICBP, patient tumors from TCGA, and breast cancer cell lines for 
in vitro experiments were classified as either the survival or growth phenotype by 
calculating the mean of scaled pathway activation values for HER, IGF1R, and AKT for 
the survival phenotype, and the mean of scaled pathway activation values for BAD, 
EGFR, KRAS, and RAF1 for the growth phenotype. Each sample was classified as 
either survival or growth phenotype based on which phenotype had the highest mean. 
Identification of additional drug response heterogeneity within  
growth factor phenotypes 
In order to classify samples into subgroups that corresponded with high and low 
HER2 activity within the survival phenotype and high and low BAD activity within the 
growth phenotype, k-means clustering (“kmeans” R function) was performed on the 
scaled pathway activity data for AKT, HER2, BAD, and EGFR pathways (with four 
means and 100 random starts). After classifying samples, t-tests were performed using 
the R function “t.test” on known HER2/AKT/PI3k/mTOR-targeting drugs and 






cell lines identified as AKT/HER2 high and AKT/HER2 low, and between the cell lines 
identified as EGFR/BAD high and EGFR/BAD low. P-values were corrected using an 
FDR correction and identified drugs that showed a significantly different drug response 
between the growth factor subgroups. When determining how growth phenotypes ER, 
PR and HER2 status performed in assessing drug responses, mean drug response 
across all available cell lines as the cut-off were used. Cell line drug sensitivity value 
above this cutoff was considered as “sensitive” and otherwise “resistant”.  
Statistical analyses 
  The “prcomp” function from the stats R package was used to compute the 
principal components in TCGA breast cancer patient RNA-seq data. The Spearman 
rank-based pairwise correlation method was used for all principal-component-based 
correlations, pathway predictions, and protein correlations. The “cor.test” function from 
the stats R package was used to calculate p-values for each correlation [93–95]. 
Student’s t-tests were used to find differences in principal component values based on 
IHC-based subtypes, mutation status within GFRN subtypes and intrinsic subtypes, 
pathway activity, drug sensitivity differences, and gene expression. The “heatmap.2” 
function from the ggplots R package and the “Heatmap” function from the 
ComplexHeatmap R package were used for generating pathway activity and pathway 
activity-drug response correlation heatmaps [96, 97]. The “lm” function from the stats R 
package was used to model PC values in TCGA using clinical subtypes, intrinsic 
subtypes, and GFRN subgroups to determine R2 values. Models were compared using 
the “anova” function from the stats package to determine the significance of adding 
additional features to the models. All analyses were conducted in R and the code is 






Availability of data and materials 
 
The datasets supporting the conclusions of this article and instructions for how to 
download it are available in the Github repository titled “GRFN_signatures” found at 
https://github.com/mumtahena/GFRN_signatures. Gene expression signatures can be 
found at GSE83083 and GSE59765. 
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Figure 3.1: High-level overview for probing growth factor receptor networks in breast 
cancer. (A) Overexpression of growth factor receptor network (GFRN) genes in HMECs: 
AKT, BAD, EGFR, HER2, IGF1R, RAF1, and KRAS (G12V). (B) Generation of RNA-
sequencing data from HMECs overexpressing GFRN genes and signature generation 
using ASSIGN. (C) Determination of GFRN pathways activation across TCGA breast 
tumors and ICBP breast cancer cell lines and identification of novel phenotypes based 
on GFRN activity. (D) Linking novel phenotypes to survival and drug response 
mechanisms in biochemical and drug response assay. 
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Figure 3.2: Analysis of pathway activity and intrinsic subtypes in (A) 1119 TCGA breast 
cancer samples and (B) 55 ICBP breast cancer cell lines. HER2, IGF1R, AKT and BAD, 
EGFR, KRAS (G12V), and RAF1 pathway activities reveal two distinct clusters that were 
negatively associated. GFRN characterization reveals a dichotomy in TCGA breast 
cancer patients, high BAD/EGFR/KRAS/RAF1 (growth phenotype) (column color label 
shown in aquamarine) and high HER2/IGF1R/AKT (survival phenotype) (column color 
label shown in coral). Subtypes determined by immunohistochemistry and intrinsic 
subtyping are shown on the right side row color labels. K-means clustering of TCGA 
samples (C) identifies subsets of samples within the survival phenotype that have high 
HER2 activation and low HER2 activation, and subsets of samples within the growth 
phenotype that have high BAD activation and low BAD activation (shown in the left side 
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row color labels). These clusters are also seen in ICBP (D).  
 
Figure 3.3: Principal component analysis across TCGA breast tumors. Correlation 
heatmap between principal component values from principle components 1 through 5 
and ASSIGN GFRN pathway estimates from TCGA breast cancer RNA-seq data. Red 












Figure 3.4: Survival and growth phenotypes differ in cell survival mechanisms. (A) The 
heatmap represents scaled activation values across 20 breast cancer cell lines used in 
this analysis for each GFRN pathway. (B) Western blot analysis for MCL-1, BIM, and B-
actin control across 20 breast cancer cell lines of either the survival phenotype or growth 
phenotype. Boxplots between samples classified as the survival phenotype or growth 
phenotype for (C) MCL-1 gene expression (log2 (Transcript per million)) in the TCGA 
data, (D) BIM gene expression (log2 (Transcript per million)) in TCGA and ICBP data, 










Figure 3.5: Growth factor receptor network phenotypes reflect dichotomous drug 
response in breast cancer cell lines. Colors correspond to scaled Spearman correlations 
between specific pathway activation estimates generated with ASSIGN and drug 
sensitivity (-logGI50) across (A) 55 breast cancer cell lines from the ICBP panel (B) 23 
breast cancer cell lines in an independent drug assay. Red represents positive 
correlation and blue represents negative correlation. Pathways cluster across the x-axis 
as (coral color) AKT growth phenotype and (green) EGFR growth phenotype. Drug 
classes are represented along the y-axis as pink (HER2/AKT/PI3K/mTOR targeted-


















































































































Figure 3.6: Differential drug response identified in GFRN phenotype heterogeneity. 
Boxplots of –log (EC50) drug response data from four drugs in the drug assay that show 
a differential drug response within growth factor phenotypes. (A) GSK1059615, a PI3K 
and mTOR inhibitor, caused an increase in response in samples within the survival 
phenotype classified as having high HER2 activity. (B) Lapatinib, a HER2 inhibitor, 
stimulated a stronger response in samples within the survival phenotype with high HER2 
activity. (C) AG1478 and (D) Gefitinib, EGFR inhibitors, caused an increased response 




































































































































































































Figure 3.7: Summary of the survival and growth phenotypes in breast cancer. The 
survival phenotype is characterized by high HER2, IGF1R, and AKT pathway activation, 
high expression of pro-apoptotic BIM, low expression of anti-apoptotic MCL-1, and 
response to HER2, AKT, PI3K, and mTOR inhibitors. The growth phenotype is 
characterized by high EGFR, KRAS, and RAF1 activation, high expression of MCL-1, 
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Supplemental Results, Figures, and Tables 
Supplemental results: Gene set enrichment analysis on  
RNA-Sequencing signatures 
We performed gene set enrichment analysis, using the Gene Set Variation 
Analysis for microarray and RNA-seq data (GSVA) method, to better understand the 
biological significance and discover enriched gene sets between our RNA-sequencing 
signatures: AKT, BAD, EGFR, HER2, IGF1R, KRAS, and RAF1 and GFP controls. We 






Signatures Database (See Methods section in manuscript). Gene sets representing cell 
cycle pathways were found to be enriched across all signatures, however, each 
signature also showed enrichment for expected and unique gene sets. For example, the 
HER2 signature was primarily enriched for immune system and cellular adhesion 
pathways (Supplemental Table 3.6). The IGF1R signature was dominated by metabolic 
pathways (Supplemental Table 3.7). The AKT signature was enriched for immune, 
apoptotic, and metabolic pathways (Supplemental Table 3.8). The BAD signature was 
enriched for immune system and cell cycle pathways (Supplemental Table 3.9). EGFR 
was dominated by DNA replication and cell cycle pathways (Supplemental Table 3.10). 
KRAS and RAF were highly enriched for MAPK pathways (Supplemental Tables 3.11- 
12), but RAF also showed enrichment for TGFB and immune system pathways 
(Supplemental Tables 3.11-12). These results highlight the variety of biological pathway 
differences which can be found by overexpressing GFRN components, further illustrating 



















Supplemental Figure 3.1: Validation of protein overexpression for each GFRN signature. 
Protein lysates from human primary mammary epithelial cells (HMECs) overexpressing 
GFRN genes were compared to GFP control protein lysates using Western blotting. (A) 
HMECs overexpressing AKT1 compared to GFP (GAPDH loading control) (B) HMECs 
overexpressing BAD, compared to GFP (β-tubulin loading control) (C) HMECs 
overexpressing EGFR and pEGFR compared to GFP (GAPDH loading control) (D) 
HMECs overexpressing HER2 and pHER2 compared to GFP (GAPDH and β-tubulin 
loading controls) (E) HMECs overexpressing IGF1R and pIGF1R (GAPDH and β-tubulin 
loading controls) (F) HMECs overexpressing pMEK compared to GFP (β-tubulin and 
GAPDH loading controls) (G) HMECs overexpressing RAF1 compared to GFP controls 







Supplemental Figure 3.2: Gene expression signatures for key GFRN pathways 
generated by ASSIGN. (A) AKT 20 gene signature, (B) BAD 250 gene signature, (C) 
EGFR 50 gene signature, (D) HER2 10 gene signature, (E) IGF1R 100 gene signature, 
(F) KRAS (G12V) 200 gene signature, and (G) RAF1 350 gene signature. The horizontal 
black bar indicates green fluorescent protein (GFP) overexpressing control samples, and 
the red bar indicates the overexpressed genes of interest (i.e., AKT1, BAD, EGFR, 








Supplemental Figure 3.3: Additional GFRN gene expression signature validations in 
TCGA breast cancer data. Pathway activity estimate boxplots between the (A) AKT 
pathway and (B) BAD pathway between PI3KCA mutated and PI3KCA wild-type TCGA 
breast cancer samples (n=787). Any mutation in PI3KCA was considered pathogenic in 
this mutation analysis. (C) HER2 pathway activation estimates between HER+ and HER- 
patient TCGA samples (n=708). Pathway activation estimates for (D) IGF1R, (E) AKT, 
(F) EGFR, and (G) RAF1 between “high“,“intermediate“, and “low“ expressing samples 
in 1119 BRCA TCGA samples. Samples with 90 percentile or higher expression were 
considered “high”, 10 percentile or lower were considered “low”, and 10 to 90 percentile 
were considered “intermediate“ expressing samples for AKT1, EGFR and RAF1. For 
IGF1R validation, samples with 80 percentile or higher IGF1R expression were 
considered “high“, 20 percentile or lower was considered “low“, and 20 to 80 percentile 








Supplemental Figure 3.4:  Pathway activity estimates between ER+ and ER- samples in 
breast cancer cell lines and patient data. (A) 19 ER- breast cancer cell lines from ICBP, 
(B) 32 ER+ breast cancer cell lines from ICBP. (C) 230 ER- breast cancer patient 
samples from TCGA, and (D) 785 ER+ breast cancer patient samples from TCGA. The 
growth phenotype is represented in aquamarine above the heat map, and the survival 
phenotype in coral. Subtypes determined by immunohistochemistry (ER, PR, and 









Supplemental Figure 3.5: Pathway activation estimates across clinical subtypes (IHC-
based, N=1012) in TCGA breast cancer data for (A) the AKT pathway (B) the BAD 
pathway (C) the HER2 pathway (D) the IGF1R pathway (E) the EGFR pathway (F) the 









Supplemental Figure 3.6: Pathway activation estimates across intrinsic subtypes 
(PAM50 based, N=510) in TCGA breast cancer data for (A) the AKT pathway (B) the 
BAD pathway (C) the EGFR pathway (D) the HER2 pathway (E) the IGF1R pathway (F) 









Supplemental Figure 3.7: Graphical representation of the IHC and intrinsic subtype 
status distribution for ICBP cell line and TCGA breast tumors. Each sample is 
represented along the X-axis and corresponding phenotype, ER, PR, HER2 and intrinsic 
subtype status is represented along the Y-axis. Supplemental Table 3.9 and 3.10 


















Supplemental Figure 3.8: Survival analysis of the four subgroups in TCGA BRCA 
samples (N=1119). Kaplan-Meier survival analysis for the four identified subgroups using 
the Peto and Peto modification of Gehan-Wilcoxon test did not show significant 










Supplemental Figure 3.9: Correlation between mean gene expression values for all 
samples and the principal component values for each sample for principal component 1 
based from breast cancer (BRCA) TCGA RNA-sequencing samples (Spearman’s 
















Supplemental Figure 3.10: Comparison of R2 values (proportion of variance) explained 
by each model for principle components (PCs) 1 through 5 from TCGA RNA-sequencing 
breast cancer data. For each PC, model variables include GFRN subtypes, intrinsic 








Supplemental Figure 3.11: Independent western blot assay for MCL-1 and BIM proteins 
between breast cancer cell lines from the survival and growth phenotypes. Lysates from 
12 cell lines from the survival phenotype (8 ER+ and 4 ER-) and 7 cell lines from the 
growth phenotype (1 ER+ and 6 ER-) were probed for anti- and pro-apoptotic proteins, 









Supplemental Figure 3.12: Correlations between pathway activation estimates and drug 
response values between ER+ and ER- and between HER+ and HER2- samples in 
breast cancer cell lines. Colors correspond to scaled Spearman correlations between 
specific pathway activation estimates generated with ASSIGN and drug sensitivity (-
logGI50) across (A) 18 ER+ breast cancer cell lines, (B) 32 ER- breast cancer cell lines 
from the ICBP panel, (C) 18 HER2+ breast cancer cell lines, and (D) 32 HER2- breast 
cancer cell lines from the ICBP panel. Red represents positive correlation and blue 
represents negative correlation. Pathways cluster across the x-axis as (coral color) 
survival phenotype and (green) growth phenotype. Drug classes are represented along 
the y-axis as pink (HER2/AKT/PI3K/mTOR targeted-therapies), yellow 



























































































































































































































Supplemental Figure 3.13: Comparison of Lapatinib sensitivity based on (A) ER status, 
(B) PR status, (C) HER2 status, (D) Intrinsic Subtypes in ICBP breast cancer cell lines. 




















Supplemental Table 3.1: Spearman correlations between pathway activation estimates 






Protein ICBP TCGA 
Correlation p-value Correlation p-value 
AKT 20 
Akt 0.576 2.03E-04 0.192 1.54E-07 
PDK1 0.574 2.14E-04 0.239 5.93E-11 
PDK1_pS241 0.535 6.50E-04 0.337 5.84E-21 
BAD 250 
Akt -0.456 4.33E-03 -0.150 4.43E-05 
PDK1 -0.605 8.14E-05 -0.313 4.37E-18 
PDK1_pS241 -0.518 1.02E-03 -0.232 2.23E-10 
EGFR 50 
EGFR 0.470 0.050 0.357 2.09E-23 
EGFR_pY1068 0.397 0.028 0.129 4.50E-04 
EGFR_pY1173   0.155 2.44E-05 
HER2 10 HER2 0.923 0.00E+00 0.376 1.61E-05 HER2_pY1248 0.953 0.00E+00 0.356 1.37E-04 
IGF1R 100 
IRS1   0.324 2.37E-19 
IGF1R 0.086 0.608   
PDK1 0.569 2.45E-04 0.371 2.68E-25 
PDK1_pS241 0.509 1.26E-03 0.403 5.33E-30 
KRAS 
(G12V) 200 
EGFR 0.423 8.57E-03 0.493 4.05E-46 
EGFR_pY1068 0.296 7.17E-02 0.089 1.60E-02 
EGFR_pY1173   0.090 1.47E-02 
MEK1   0.116 1.69E-03 
RAF 350 
MEK1 0.285 0.084 0.245 1.72E-11 
PKC.alpha 0.467 3.46E-03 0.396 6.36E-29 

























Supplemental Table 3.2: Top 50 gene sets predicted by GSVA between GFP (control) 
and HER2 overexpressing RNA-sequencing data in HMECs. Distinguishing pathways 
are color coded. 
 
Hallmark + canonical (C2) gene sets (Molecular Signatures Database) P.Value adj.P.Val 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION <0.0001 <0.0001 
REACTOME_IL_7_SIGNALING <0.0001 <0.0001 
REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES <0.0001 <0.0001 
BIOCARTA_CBL_PATHWAY <0.0001 <0.0001 
BIOCARTA_COMP_PATHWAY <0.0001 <0.0001 
PID_VEGFR1_PATHWAY <0.0001 <0.0001 
ST_G_ALPHA_S_PATHWAY <0.0001 <0.0001 
BIOCARTA_EPONFKB_PATHWAY <0.0001 <0.0001 
REACTOME_CELL_EXTRACELLULAR_MATRIX_INTERACTIONS <0.0001 <0.0001 
BIOCARTA_RB_PATHWAY <0.0001 0.0001 
BIOCARTA_IL22BP_PATHWAY <0.0001 0.0001 
BIOCARTA_IL10_PATHWAY <0.0001 0.0001 
BIOCARTA_P53HYPOXIA_PATHWAY <0.0001 0.0001 
KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION <0.0001 0.0001 
REACTOME_REGULATION_OF_IFNA_SIGNALING <0.0001 0.0002 
KEGG_OOCYTE_MEIOSIS <0.0001 0.0003 
REACTOME_RECYCLING_PATHWAY_OF_L1 <0.0001 0.0003 
BIOCARTA_SPRY_PATHWAY <0.0001 0.0003 
KEGG_FOCAL_ADHESION <0.0001 0.0003 
BIOCARTA_IL7_PATHWAY <0.0001 0.0003 
PID_REELINPATHWAY <0.0001 0.0003 
KEGG_GAP_JUNCTION <0.0001 0.0004 
PID_ILK_PATHWAY <0.0001 0.0005 
REACTOME_SEMAPHORIN_INTERACTIONS <0.0001 0.0005 
PID_NECTIN_PATHWAY <0.0001 0.0006 
REACTOME_SIGNALING_BY_RHO_GTPASES <0.0001 0.0006 
REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS <0.0001 0.0006 
PID_INTEGRIN_A9B1_PATHWAY <0.0001 0.0007 
REACTOME_KINESINS <0.0001 0.0007 
KEGG_SELENOAMINO_ACID_METABOLISM <0.0001 0.0007 
PID_INTEGRIN_A4B1_PATHWAY <0.0001 0.0008 
REACTOME_PLATELET_HOMEOSTASIS <0.0001 0.0008 
REACTOME_GRB2_EVENTS_IN_ERBB2_SIGNALING <0.0001 0.0008 
KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND… <0.0001 0.0008 
REACTOME_G0_AND_EARLY_G1 <0.0001 0.0008 
BIOCARTA_CELLCYCLE_PATHWAY <0.0001 0.0008 
PID_AURORA_A_PATHWAY <0.0001 0.0008 
PID_S1P_S1P1_PATHWAY <0.0001 0.0009 
HALLMARK_GLYCOLYSIS <0.0001 0.0009 
HALLMARK_INTERFERON_GAMMA_RESPONSE <0.0001 0.0009 
REACTOME_P75NTR_RECRUITS_SIGNALLING_COMPLEXES <0.0001 0.0009 
PID_ERBB_NETWORK_PATHWAY <0.0001 0.0009 
KEGG_CALCIUM_SIGNALING_PATHWAY <0.0001 0.0009 
REACTOME_SIGNALING_BY_FGFR1_FUSION_MUTANTS <0.0001 0.0009 
BIOCARTA_NO1_PATHWAY <0.0001 0.0009 
REACTOME_METABOLISM_OF_POLYAMINES <0.0001 0.0010 
KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM <0.0001 0.0010 
REACTOME_BOTULINUM_NEUROTOXICITY <0.0001 0.0010 






Supplemental Table 3.3: Top 50 gene sets predicted by GSVA between GFP (control) 
and IGF1R overexpressing RNA-sequencing data in HMECs. Distinguishing pathways 
are color coded. 
 
Hallmark + canonical (C2) gene sets (Molecular Signatures Database) P.Value adj.P.Val 
REACTOME_AMINO_ACID_SYNTHESIS_AND_INTERCONVERSION… <0.0001 <0.0001 
KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM <0.0001 <0.0001 
REACTOME_DIABETES_PATHWAYS <0.0001 <0.0001 
PID_ATF2_PATHWAY <0.0001 <0.0001 
REACTOME_UNFOLDED_PROTEIN_RESPONSE <0.0001 <0.0001 
REACTOME_IL_6_SIGNALING <0.0001 <0.0001 
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S <0.0001 <0.0001 
HALLMARK_UNFOLDED_PROTEIN_RESPONSE <0.0001 <0.0001 
REACTOME_ACTIVATION_OF_GENES_BY_ATF4 <0.0001 <0.0001 
PID_IL23PATHWAY <0.0001 <0.0001 
REACTOME_PERK_REGULATED_GENE_EXPRESSION <0.0001 <0.0001 
REACTOME_SYNTHESIS_OF_SUBSTRATES_IN_N_GLYCAN… <0.0001 <0.0001 
KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM <0.0001 <0.0001 
REACTOME_ACTIVATION_OF_CHAPERONES_BY_ATF6_ALPHA <0.0001 <0.0001 
HALLMARK_CHOLESTEROL_HOMEOSTASIS <0.0001 <0.0001 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION <0.0001 <0.0001 
HALLMARK_MTORC1_SIGNALING <0.0001 <0.0001 
KEGG_NITROGEN_METABOLISM <0.0001 <0.0001 
BIOCARTA_CYTOKINE_PATHWAY <0.0001 <0.0001 
BIOCARTA_GRANULOCYTES_PATHWAY <0.0001 <0.0001 
REACTOME_SYNTHESIS_SECRETION_AND_INACTIVATION_OF… <0.0001 <0.0001 
ST_STAT3_PATHWAY <0.0001 <0.0001 
KEGG_PROTEIN_EXPORT <0.0001 <0.0001 
KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM <0.0001 <0.0001 
KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM <0.0001 <0.0001 
REACTOME_GLUCONEOGENESIS <0.0001 <0.0001 
REACTOME_BASIGIN_INTERACTIONS <0.0001 <0.0001 
PID_REG_GR_PATHWAY <0.0001 <0.0001 
BIOCARTA_ERYTH_PATHWAY <0.0001 <0.0001 
BIOCARTA_IL10_PATHWAY <0.0001 <0.0001 
REACTOME_BIOSYNTHESIS_OF_THE_N_GLYCAN_PRECURSOR.. <0.0001 <0.0001 
PID_AP1_PATHWAY <0.0001 <0.0001 
KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY <0.0001 <0.0001 
PID_NECTIN_PATHWAY <0.0001 <0.0001 
PID_P38ALPHABETADOWNSTREAMPATHWAY <0.0001 <0.0001 
BIOCARTA_TEL_PATHWAY <0.0001 <0.0001 
BIOCARTA_LAIR_PATHWAY <0.0001 <0.0001 
BIOCARTA_IGF1MTOR_PATHWAY <0.0001 <0.0001 
REACTOME_CIRCADIAN_CLOCK <0.0001 <0.0001 
REACTOME_BMAL1_CLOCK_NPAS2_ACTIVATES_CIRCADIAN… <0.0001 <0.0001 
BIOCARTA_IL6_PATHWAY <0.0001 <0.0001 
REACTOME_INCRETIN_SYNTHESIS_SECRETION_AND_INACT… <0.0001 <0.0001 
REACTOME_PLATELET_ADHESION_TO_EXPOSED_COLLAGEN <0.0001 <0.0001 
BIOCARTA_LYM_PATHWAY <0.0001 <0.0001 
HALLMARK_GLYCOLYSIS <0.0001 <0.0001 
PID_CDC42_REG_PATHWAY <0.0001 <0.0001 
BIOCARTA_TALL1_PATHWAY <0.0001 <0.0001 
REACTOME_ASSOCIATION_OF_LICENSING_FACTORS … <0.0001 <0.0001 








Supplemental Table 3.4: Top 50 gene sets predicted by GSVA between GFP (control) 
and AKT1 overexpressing RNA-sequencing data in HMECs. Expected pathways are in 
red. 
 
Hallmark + canonical (C2) gene sets (Molecular Signatures Database) P.Value adj.P.Val 
REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES <0.0001 <0.0001 
REACTOME_REVERSIBLE_HYDRATION_OF_CARBON_DIOXIDE <0.0001 <0.0001 
BIOCARTA_RB_PATHWAY <0.0001 <0.0001 
KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM <0.0001 <0.0001 
REACTOME_GLYCOLYSIS <0.0001 <0.0001 
REACTOME_SIGNALING_BY_BMP <0.0001 <0.0001 
REACTOME_DOWNREGULATION_OF_SMAD2_3_SMAD4_TRANSCRIP… <0.0001 <0.0001 
REACTOME_TRANSCRIPTIONAL_ACTIVITY_OF_SMAD2_SMAD3_SM… <0.0001 <0.0001 
PID_SYNDECAN_2_PATHWAY <0.0001 <0.0001 
PID_NECTIN_PATHWAY <0.0001 <0.0001 
REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRES… <0.0001 <0.0001 
REACTOME_SIGNAL_ATTENUATION <0.0001 <0.0001 
REACTOME_GLUCOSE_METABOLISM <0.0001 <0.0001 
PID_RHOA_PATHWAY <0.0001 <0.0001 
BIOCARTA_P53_PATHWAY <0.0001 <0.0001 
PID_P53DOWNSTREAMPATHWAY <0.0001 <0.0001 
REACTOME_FORMATION_OF_TUBULIN_FOLDING_INTERMEDIATES … <0.0001 0.0001 
REACTOME_RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL … <0.0001 0.0001 
REACTOME_PECAM1_INTERACTIONS <0.0001 0.0001 
HALLMARK_WNT_BETA_CATENIN_SIGNALING <0.0001 0.0001 
KEGG_PENTOSE_PHOSPHATE_PATHWAY <0.0001 0.0001 
BIOCARTA_CBL_PATHWAY <0.0001 0.0002 
BIOCARTA_AMI_PATHWAY <0.0001 0.0002 
HALLMARK_TNFA_SIGNALING_VIA_NFKB <0.0001 0.0002 
REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_BETA_CELLS <0.0001 0.0003 
REACTOME_CELL_EXTRACELLULAR_MATRIX_INTERACTIONS <0.0001 0.0003 
REACTOME_BILE_SALT_AND_ORGANIC_ANION_SLC_TRANSPORT… <0.0001 0.0003 
REACTOME_ZINC_TRANSPORTERS <0.0001 0.0003 
BIOCARTA_NTHI_PATHWAY <0.0001 0.0004 
PID_REG_GR_PATHWAY <0.0001 0.0004 
KEGG_HOMOLOGOUS_RECOMBINATION <0.0001 0.0004 
PID_HIF1_TFPATHWAY <0.0001 0.0004 
REACTOME_GLUCONEOGENESIS <0.0001 0.0004 
BIOCARTA_DNAFRAGMENT_PATHWAY <0.0001 0.0004 
BIOCARTA_DC_PATHWAY <0.0001 0.0004 
BIOCARTA_ECM_PATHWAY <0.0001 0.0004 
REACTOME_RNA_POL_III_TRANSCRIPTION <0.0001 0.0004 
REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING <0.0001 0.0004 
REACTOME_P75NTR_RECRUITS_SIGNALLING_COMPLEXES <0.0001 0.0004 
BIOCARTA_GRANULOCYTES_PATHWAY <0.0001 0.0005 
BIOCARTA_ARAP_PATHWAY <0.0001 0.0005 
REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOP… <0.0001 0.0005 
REACTOME_REGULATION_OF_RHEB_GTPASE_ACTIVITY_BY_AMPK <0.0001 0.0005 
HALLMARK_IL6_JAK_STAT3_SIGNALING <0.0001 0.0005 
PID_TOLL_ENDOGENOUS_PATHWAY <0.0001 0.0006 
REACTOME_HS_GAG_BIOSYNTHESIS <0.0001 0.0006 
REACTOME_RECYCLING_PATHWAY_OF_L1 <0.0001 0.0006 
PID_FAK_PATHWAY <0.0001 0.0006 







Supplemental Table 3.5: Top 50 gene sets predicted by GSVA between GFP (control) 
and BAD overexpressing RNA-sequencing data in HMECs Expected pathways are in 
red. 
 
Hallmark + canonical (C2) gene sets (Molecular Signatures Database) P.Value adj.P.Val 
REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES <0.0001 <0.0001 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION <0.0001 <0.0001 
BIOCARTA_INFLAM_PATHWAY <0.0001 <0.0001 
BIOCARTA_NTHI_PATHWAY <0.0001 <0.0001 
PID_FRA_PATHWAY <0.0001 <0.0001 
PID_SYNDECAN_2_PATHWAY <0.0001 <0.0001 
PID_ATF2_PATHWAY <0.0001 <0.0001 
BIOCARTA_P53HYPOXIA_PATHWAY <0.0001 <0.0001 
BIOCARTA_TID_PATHWAY <0.0001 <0.0001 
PID_SYNDECAN_3_PATHWAY <0.0001 <0.0001 
BIOCARTA_PPARA_PATHWAY <0.0001 <0.0001 
HALLMARK_TNFA_SIGNALING_VIA_NFKB <0.0001 <0.0001 
PID_REG_GR_PATHWAY <0.0001 <0.0001 
BIOCARTA_IL7_PATHWAY <0.0001 <0.0001 
BIOCARTA_FREE_PATHWAY <0.0001 <0.0001 
BIOCARTA_IL10_PATHWAY <0.0001 <0.0001 
PID_AP1_PATHWAY <0.0001 <0.0001 
REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS <0.0001 <0.0001 
BIOCARTA_STEM_PATHWAY <0.0001 <0.0001 
BIOCARTA_IL17_PATHWAY <0.0001 <0.0001 
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION <0.0001 <0.0001 
PID_RHOA_PATHWAY <0.0001 <0.0001 
PID_IL8CXCR1_PATHWAY <0.0001 <0.0001 
BIOCARTA_ARENRF2_PATHWAY <0.0001 <0.0001 
BIOCARTA_GRANULOCYTES_PATHWAY <0.0001 <0.0001 
PID_NFAT_TFPATHWAY <0.0001 <0.0001 
BIOCARTA_CYTOKINE_PATHWAY <0.0001 <0.0001 
BIOCARTA_ERYTH_PATHWAY <0.0001 <0.0001 
BILD_HRAS_ONCOGENIC_SIGNATURE <0.0001 <0.0001 
PID_IL23PATHWAY <0.0001 <0.0001 
REACTOME_RNA_POL_III_CHAIN_ELONGATION <0.0001 <0.0001 
KEGG_RNA_POLYMERASE <0.0001 <0.0001 
KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER… <0.0001 <0.0001 
REACTOME_RNA_POL_III_TRANSCRIPTION_INITIATION_FROM_TYP
E_3 <0.0001 <0.0001 
BIOCARTA_IL22BP_PATHWAY <0.0001 <0.0001 
BIOCARTA_ETS_PATHWAY <0.0001 <0.0001 
BIOCARTA_CHEMICAL_PATHWAY <0.0001 <0.0001 
REACTOME_RNA_POL_III_TRANSCRIPTION_TERMINATION <0.0001 <0.0001 
KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY <0.0001 <0.0001 
KEGG_PRION_DISEASES <0.0001 <0.0001 
REACTOME_G_ALPHA_I_SIGNALLING_EVENTS <0.0001 <0.0001 
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY <0.0001 <0.0001 
PID_TAP63PATHWAY <0.0001 <0.0001 
PID_P53DOWNSTREAMPATHWAY <0.0001 <0.0001 
REACTOME_IL_6_SIGNALING <0.0001 <0.0001 
HALLMARK_IL6_JAK_STAT3_SIGNALING <0.0001 <0.0001 
KEGG_ENDOCYTOSIS <0.0001 <0.0001 
PID_FGF_PATHWAY <0.0001 <0.0001 






Supplemental Table 3.6. Top 50 gene sets predicted by GSVA between GFP (control) 
and EGFR overexpressing RNA-sequencing data in HMECs. Expected pathways are in 
red. 
 
Hallmark + canonical (C2) gene sets (Molecular Signatures Database) P.Value 
adj.P.V
al 
REACTOME_UNWINDING_OF_DNA <0.0001 <0.0001 
REACTOME_DNA_STRAND_ELONGATION <0.0001 <0.0001 
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX <0.0001 <0.0001 
REACTOME_CYCLIN_A_B1_ASSOCIATED_EVENTS_DURING_G2_M_TRA
NS… <0.0001 <0.0001 
KEGG_DNA_REPLICATION <0.0001 <0.0001 
PID_FANCONI_PATHWAY <0.0001 <0.0001 
REACTOME_G1_S_SPECIFIC_TRANSCRIPTION <0.0001 <0.0001 
REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION.. <0.0001 <0.0001 
REACTOME_G2_M_CHECKPOINTS <0.0001 <0.0001 
HALLMARK_E2F_TARGETS <0.0001 <0.0001 
PID_FOXM1PATHWAY <0.0001 <0.0001 
REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_REPLICATION <0.0001 <0.0001 
PID_ATR_PATHWAY <0.0001 <0.0001 
BIOCARTA_MCM_PATHWAY <0.0001 <0.0001 
REACTOME_MITOTIC_PROMETAPHASE <0.0001 <0.0001 
REACTOME_DNA_REPLICATION <0.0001 <0.0001 
KEGG_CELL_CYCLE <0.0001 <0.0001 
HALLMARK_G2M_CHECKPOINT <0.0001 <0.0001 
REACTOME_G0_AND_EARLY_G1 <0.0001 <0.0001 
REACTOME_POL_SWITCHING <0.0001 <0.0001 
REACTOME_MITOTIC_M_M_G1_PHASES <0.0001 <0.0001 
REACTOME_REPAIR_SYNTHESIS_FOR_GAP_FILLING_BY_DNA_POL_… <0.0001 <0.0001 
REACTOME_LAGGING_STRAND_SYNTHESIS <0.0001 <0.0001 
REACTOME_CELL_CYCLE_MITOTIC <0.0001 <0.0001 
REACTOME_EXTENSION_OF_TELOMERES <0.0001 <0.0001 
KEGG_MISMATCH_REPAIR <0.0001 <0.0001 
REACTOME_SYNTHESIS_OF_DNA <0.0001 <0.0001 
REACTOME_INHIBITION_OF_REPLICATION_INITIATION_OF_DAMAGED_
DNA.. <0.0001 <0.0001 
BIOCARTA_MCM_PATHWAY <0.0001 <0.0001 
REACTOME_CDC6_ASSOCIATION_WITH_THE_ORC_ORIGIN_COMPLEX <0.0001 <0.0001 
PID_AURORA_B_PATHWAY <0.0001 <0.0001 
BIOCARTA_CELLCYCLE_PATHWAY <0.0001 <0.0001 
PID_PLK1_PATHWAY <0.0001 <0.0001 
REACTOME_S_PHASE <0.0001 <0.0001 
REACTOME_CELL_CYCLE <0.0001 <0.0001 
REACTOME_HOMOLOGOUS_RECOMBINATION_REPAIR_OF_REPLICA… <0.0001 <0.0001 
PID_E2F_PATHWAY <0.0001 <0.0001 
REACTOME_MITOTIC_G1_G1_S_PHASES <0.0001 <0.0001 
REACTOME_M_G1_TRANSITION <0.0001 <0.0001 
REACTOME_KINESINS <0.0001 <0.0001 
REACTOME_G1_S_TRANSITION <0.0001 <0.0001 
REACTOME_CHROMOSOME_MAINTENANCE <0.0001 <0.0001 
REACTOME_E2F_ENABLED_INHIBITION_OF_PRE_REPLICATION_CO… <0.0001 <0.0001 
KEGG_HOMOLOGOUS_RECOMBINATION <0.0001 <0.0001 
SA_REG_CASCADE_OF_CYCLIN_EXPR <0.0001 <0.0001 
PID_BARD1PATHWAY <0.0001 <0.0001 
REACTOME_ASSOCIATION_OF_LICENSING_FACTORS_WITH_THE_P… <0.0001 <0.0001 






Supplemental Table 3.7. Top 50 gene sets predicted by GSVA between GFP (control) 
and KRAS(G12V) overexpressing RNA-sequencing data in HMECs. Expected pathways 
are in bold. 
 
 
Hallmark + canonical (C2) gene sets (Molecular Signatures Database) P.Value adj.P.Val 
REACTOME_RAF_MAP_KINASE_CASCADE <0.0001 <0.0001 
PID_TCRRASPATHWAY <0.0001 <0.0001 
REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING <0.0001 <0.0001 
REACTOME_SHC_MEDIATED_SIGNALLING <0.0001 <0.0001 
REACTOME_GRB2_EVENTS_IN_ERBB2_SIGNALING <0.0001 <0.0001 
REACTOME_SHC1_EVENTS_IN_ERBB4_SIGNALING <0.0001 <0.0001 
REACTOME_SHC_RELATED_EVENTS <0.0001 <0.0001 
BIOCARTA_P53HYPOXIA_PATHWAY <0.0001 <0.0001 
REACTOME_P38MAPK_EVENTS <0.0001 <0.0001 
REACTOME_SOS_MEDIATED_SIGNALLING <0.0001 <0.0001 
PID_RAS_PATHWAY <0.0001 <0.0001 
BILD_HRAS_ONCOGENIC_SIGNATURE <0.0001 <0.0001 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION <0.0001 <0.0001 
REACTOME_IL_7_SIGNALING <0.0001 <0.0001 
PID_ERBB_NETWORK_PATHWAY <0.0001 <0.0001 
REACTOME_SIGNALLING_TO_P38_VIA_RIT_AND_RIN <0.0001 <0.0001 
BIOCARTA_IL7_PATHWAY <0.0001 <0.0001 
KEGG_ALDOSTERONE_REGULATED_SODIUM_REABSORPTION <0.0001 <0.0001 
BIOCARTA_TID_PATHWAY <0.0001 <0.0001 
PID_MAPKTRKPATHWAY <0.0001 <0.0001 
PID_CD8TCRDOWNSTREAMPATHWAY <0.0001 <0.0001 
HALLMARK_ANGIOGENESIS <0.0001 <0.0001 
REACTOME_ARMS_MEDIATED_ACTIVATION <0.0001 <0.0001 
BIOCARTA_SPRY_PATHWAY <0.0001 <0.0001 
REACTOME_TIE2_SIGNALING <0.0001 <0.0001 
BIOCARTA_PPARA_PATHWAY <0.0001 <0.0001 
HALLMARK_KRAS_SIGNALING_UP <0.0001 <0.0001 
REACTOME_NUCLEOTIDE_LIKE_PURINERGIC_RECEPTORS <0.0001 <0.0001 
HALLMARK_APICAL_SURFACE <0.0001 <0.0001 
KEGG_ENDOCYTOSIS <0.0001 <0.0001 
KEGG_SPLICEOSOME <0.0001 <0.0001 
REACTOME_SIGNALING_BY_CONSTITUTIVELY_ACTIVE_EGFR <0.0001 <0.0001 
REACTOME_HYALURONAN_METABOLISM <0.0001 <0.0001 
PID_ER_NONGENOMIC_PATHWAY <0.0001 <0.0001 
BIOCARTA_MAL_PATHWAY <0.0001 <0.0001 
REACTOME_SIGNALLING_TO_RAS <0.0001 <0.0001 
HALLMARK_IL2_STAT5_SIGNALING <0.0001 <0.0001 
BIOCARTA_TEL_PATHWAY <0.0001 <0.0001 
REACTOME_TRIGLYCERIDE_BIOSYNTHESIS <0.0001 <0.0001 
PID_P38ALPHABETAPATHWAY <0.0001 <0.0001 
REACTOME_SHC_MEDIATED_CASCADE <0.0001 <0.0001 
BIOCARTA_EPONFKB_PATHWAY <0.0001 <0.0001 
BIOCARTA_FIBRINOLYSIS_PATHWAY <0.0001 <0.0001 
ST_JNK_MAPK_PATHWAY <0.0001 <0.0001 
REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS <0.0001 <0.0001 
REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_A
ND_MAPK <0.0001 <0.0001 
PID_ERBB2ERBB3PATHWAY <0.0001 <0.0001 






Supplemental Table 3.8. Top 50 gene sets predicted by GSVA between GFP (control) 
and RAF1 overexpressing RNA-sequencing data in HMECs. Expected pathways are in 
red. 
 
Hallmark + canonical (C2) gene sets (Molecular Signatures Database) P.Value adj.P.Val 
BIOCARTA_SPRY_PATHWAY <0.0001 <0.0001 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION <0.0001 <0.0001 
HALLMARK_KRAS_SIGNALING_UP <0.0001 <0.0001 
PID_REELINPATHWAY <0.0001 <0.0001 
BIOCARTA_CBL_PATHWAY <0.0001 <0.0001 
REACTOME_REVERSIBLE_HYDRATION_OF_CARBON_DIO… <0.0001 <0.0001 
BIOCARTA_FIBRINOLYSIS_PATHWAY <0.0001 <0.0001 
PID_VEGFR1_PATHWAY <0.0001 <0.0001 
PID_INTEGRIN_A9B1_PATHWAY <0.0001 <0.0001 
BIOCARTA_SPPA_PATHWAY <0.0001 <0.0001 
BIOCARTA_IL10_PATHWAY <0.0001 <0.0001 
PID_BMPPATHWAY <0.0001 <0.0001 
SIG_IL4RECEPTOR_IN_B_LYPHOCYTES <0.0001 <0.0001 
BIOCARTA_P53HYPOXIA_PATHWAY <0.0001 <0.0001 
PID_ERBB1_INTERNALIZATION_PATHWAY <0.0001 <0.0001 
HALLMARK_TGF_BETA_SIGNALING <0.0001 <0.0001 
PID_IGF1_PATHWAY <0.0001 <0.0001 
SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES <0.0001 <0.0001 
BIOCARTA_AKAP13_PATHWAY <0.0001 <0.0001 
PID_TGFBRPATHWAY <0.0001 <0.0001 
PID_FGF_PATHWAY <0.0001 <0.0001 
REACTOME_DOWNREGULATION_OF_SMAD2_3_SMAD4_TR. <0.0001 <0.0001 
HALLMARK_IL2_STAT5_SIGNALING <0.0001 <0.0001 
BIOCARTA_IL22BP_PATHWAY <0.0001 <0.0001 
KEGG_SPLICEOSOME <0.0001 <0.0001 
SIG_BCR_SIGNALING_PATHWAY <0.0001 <0.0001 
REACTOME_SIGNAL_TRANSDUCTION_BY_L1 <0.0001 <0.0001 
KEGG_ASCORBATE_AND_ALDARATE_METABOLISM <0.0001 <0.0001 
REACTOME_RECYCLING_PATHWAY_OF_L1 <0.0001 <0.0001 
REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COM… <0.0001 <0.0001 
REACTOME_DOWNREGULATION_OF_TGF_BETA_RECEPTOR <0.0001 <0.0001 
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY <0.0001 <0.0001 
KEGG_JAK_STAT_SIGNALING_PATHWAY <0.0001 <0.0001 
REACTOME_SIGNALING_BY_BMP <0.0001 <0.0001 
REACTOME_TRANSCRIPTIONAL_ACTIVITY_OF_SMAD2_SM.. <0.0001 <0.0001 
REACTOME_RORA_ACTIVATES_CIRCADIAN_EXPRESSION <0.0001 <0.0001 
PID_EPHRINBREVPATHWAY <0.0001 <0.0001 
REACTOME_IL_7_SIGNALING <0.0001 <0.0001 
KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION <0.0001 <0.0001 
REACTOME_G_ALPHA1213_SIGNALLING_EVENTS <0.0001 <0.0001 
PID_P38_MK2PATHWAY <0.0001 <0.0001 
REACTOME_GAP_JUNCTION_TRAFFICKING <0.0001 <0.0001 
KEGG_FATTY_ACID_METABOLISM <0.0001 <0.0001 
KEGG_PRION_DISEASES <0.0001 <0.0001 
REACTOME_TGF_BETA_RECEPTOR_SIGNALING_ACTIVAT… <0.0001 <0.0001 
PID_ARF6_PATHWAY <0.0001 <0.0001 
BIOCARTA_ECM_PATHWAY <0.0001 <0.0001 
BILD_HRAS_ONCOGENIC_SIGNATURE <0.0001 <0.0001 






Supplemental Table 3.9: Clinical and intrinsic subtype variation within the growth and 



















ER Positive 17 58.62% 1 3.84% 
ER Negative 10 34.48% 22 84.62% 
PR Positive 7 24.14% 0 0% 
PR Negative 20 68.96% 21 80.76% 
HER2 Positive 15 51.72% 2 7.69% 
HER2 Negative 14 48.28% 19 73.07% 
Basal 1 3.45% 9 34.62% 
Claudin-low 0 0% 5 19.23% 
HER2-Basal 1 3.45% 6 23.08% 
HER2-Luminal 14 48.28% 0 0% 





























Supplemental Table 3.10: Clinical and intrinsic subtype variation within the growth and 
survival phenotypes in TCGA tumor data. 
 
















ER Positive 505 84.73% 280 53.54% 
ER Negative 33 5.54% 197 37.67% 
PR Positive 435 72.99% 245 46.85% 
PR Negative 102 17.11% 230 43.98% 
HER2 
Positive 
108 18.12% 54 10.33% 
HER2 
Negative 
251 42.11% 295 56.41% 
Basal 2 0.34% 93 17.78% 
HER2 41 6.88% 16 3.06% 
LumA 158 26.51% 73 13.96% 
LumB 106 17.79% 21 4.02% 
























Supplemental Table 3.11: Comparing GFRN subtypes, intrinsic subtypes (PAM50), and 
clinical subtypes (ER, ER, and HER2 status) in terms of contribution to principle 
components 1 through 5 from TCGA RNA-sequencing breast cancer data. Contributed 
variability from linear models are represented as R2 values (0-1).  
PC ER (R2) 
ER + GFRN 
subgroups (R2) ER + PAM50 (R2) 
1 0.087 0.188 0.131 
2 0.561 0.696 0.747 
3 0.052 0.398 0.254 
4 0.029 0.279 0.078 
5 0.038 0.175 0.216 
    
PC PR  
PR + GFRN 
subgroups PR + PAM50 
1 0.060 0.156 0.124 
2 0.407 0.647 0.736 
3 0.059 0.393 0.253 
4 0.004 0.282 0.083 
5 0.027 0.173 0.216 
    
PC HER2 
HER2 + GFRN 
subgroups HER2 + PAM50 
1 0.011 0.129 0.125 
2 0.000 0.509 0.725 
3 0.033 0.393 0.257 
4 0.021 0.279 0.082 
5 0.023 0.207 0.224 






1 0.098 0.191 0.133 
2 0.598 0.726 0.751 
3 0.091 0.404 0.263 
4 0.054 0.282 0.089 
5 0.068 0.213 0.224 






ER/PR/HER2 + PAM50 +GFRN 
subgroups 
1 0.124427 0.1229359 0.2100966 0.220723 
2 0.4922497 0.7243437 0.7920581 0.8151674 
3 0.3845233 0.2489111 0.4695138 0.4784226 
4 0.2788131 0.0777884 0.2880172 0.2936144 






 Supplemental Table 3.12: Spearman correlations between principal component values 
for principal components 1-5 from TCGA BRCA gene expression data and pathway 
activation estimates for each oncogenic signature in TCGA BRCA gene expression data 
(*  p-value<0.0001). 
 
    PC 1 PC 2 PC 3 PC 4 PC 5 
AKT 0.047 -0.572* 0.402* 0.474* 0.084 
HER2 -0.076 -0.334* 0.366* 0.347* -0.094 
IGF1R -0.284* -0.824* 0.249* 0.358* 0.044 
EGFR -0.255* 0.439* -0.538* -0.596* -0.266* 
RAF1 -0.357* 0.639* -0.434* -0.636* -0.347* 
KRAS  0.108 0.762* -0.399* -0.443* -0.065 






Supplemental Table 3.13: List of cancer drugs and corresponding p-values, where 
GFRN phenotypes, ER, PR, or HER2 status could significantly (p-value<0.05) 



















01 AG1478 0.014 
AKT1/2 
Inhibitor 0.028 AG1478 0.001 
AZD6244 0.007 
AKT1/2 
Inhibitor 0.034 Triciribine 0.001 BEZ235 0.024 
CGC.11047 0.006 Bortezomib 0.041 AS.252424 0.029 
BIBW29
92 0.000 
Erlotinib 0.012 CGC.11047 0.027 AZD6244 0.000 CPT.11 0.040 
Etoposide 0.034 Erlotinib 0.001 GSK1070916 0.047 
Everoli
mus 0.020 
Everolimus 0.001 GSK461364 0.004 GSK1120212 0.000 
GSK183
8705 0.015 
Fascaplysin 0.004 GSK2119563 0.049 GSK461364 0.001 
GSK211
9563 0.029 
GSK1070916 0.035 MG.132 0.017 ICRF.193 0.000 
GSK212
6458 0.004 
GSK1120212 0.003 PF.4691502 0.041 PF.3814735 0.023 
GSK105
9615 0.021 
GSK1059868 0.018 Vorinostat 0.022 Pemetrexed 0.000 
GSK650
394 0.038 
GSK461364 0.016 Bosutinib 0.018 VX.680 0.020 
Lapatini
b 0.000 
GSK2119563 0.022 Tamoxifen 0.044 ZM447439 0.010 
Geldana
mycin 0.021 




    
NU6102 0.000 
GSK650394 0.029 
















    
VX.680 0.019 
NU6102 0.028 
      PF.4691502 0.000 
      Rapamycin 0.001 
      Vorinostat 0.001 
      Bosutinib 0.003 
      Sunitinib.Mala
te 0.015 
      Temsirolimus 0.032 
      Trichostatin.A 0.000 






Supplemental Table 3.14: ASSIGN parameters used for all analyses. The default 
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Bioinformatics and is authored by Shelley M. MacNeil*, Anant Asthana, Jasmine A. 
McQuerry, JT Olds, Stephen R. Piccolo, and Andrea H. Bild. 
 
*denotes first authorship 
 
Contributed to: study design, manuscript writing and editing, software development and 







  Gene set analysis (GSA), a powerful technique for interpreting high-throughput 
genomic data, helps uncover differences between biological phenotypes at the gene-set 
level. However, most GSA methods support transcriptomic data but lack support for 
multiomic data integration. This limits our potential to obtain comprehensive views of 
complex molecular systems best explained by multiple “omic” data types, such as 
cancer. Also, many GSA methods require bioinformatic experience. Therefore, we have 
created a user-friendly web application, GSOA-Shiny, which enables users to perform 
multiomic GSA analyses using our previously developed Gene Set Omic Analysis 
(GSOA) method. GSOA-Shiny uses machine learning to account for complex 
interactions across multiple molecular variations, supporting DNA, RNA, protein, and 
epigenetic data and combinations thereof. GSOA-Shiny provides extensive 
documentation, an intuitive, HTML-based report, and a novel “hallmark” analysis. These 
features make multiomic GSA analysis more accessible for biologists, including those 
without programing expertise.  
 
Availability  
 GSOA-Shiny can be accessed from https://gsoa-app.org/ from any web browser. 
It is developed exclusively in the R programing-language and can be downloaded from 
GitHub and launched locally on operating systems that support R, including Windows, 




Cellular events are tightly regulated at the genome, transcriptome, epigenome, 






provide more biologically relevant information than observing one data type in isolation, 
especially for complex molecular diseases, such as cancer [2]. High-throughput 
technologies exist for profiling many molecule types, including single-nucleotide variants 
(SNV), copy-number variants (CNV), messenger RNA (mRNA), microRNA (miRNA), 
epigenetic variations, and protein expression levels [3]. Large comprehensive studies, 
such as The Cancer Genome Atlas (TCGA), have generated massive volumes of high-
dimensional data [4]; however, combining different data types is computationally and 
quantitatively challenging, and requires techniques beyond the capability of most 
biologists [5].  
One method which has revolutionized the interpretation of molecular data is gene 
set analysis (GSA), which uses varying statistical methods to identify enriched gene sets 
that share biochemical or cellular functions and that differ between biological phenotypes 
[6]. Results from these methods may be used to guide uncovering mechanisms 
underlying biological phenomena GSA methods, originally designed for transcriptomic 
data [7], have been expanded to DNA methylation [8], ChIP-sequencing [9], and SNP 
data [10], albeit typically in isolation. Integrative multiomic methods have recently been 
developed that combine specific combinations of molecular data, including SNPs and 
gene expression levels [11]; miRNA and gene expression levels [12]; and proteomics, 
metabolomics, SNP, and gene expression data [13]. However, these methods tend to 
rely on basic test statistics and ignore gene interactions. In addition, most methods aim 
to identify gene sets that are either up- or down-regulated as a whole [14]. Standalone 
and web-based applications do exist, but they can be challenging to use without 
bioinformatic skills, creating hurdles for biologists [15]. Therefore, more user-friendly web 
applications are required for wide adoption of multiomic GSA methods among the 






Here, we present GSOA-Shiny, an easy-to-use, R-shiny-based web application 
for the analysis of multiomic data. GSOA-Shiny is an improved version of our previously 
published package, Gene Set Omic Analysis (GSOA), which uses machine learning 
algorithms to integrate multiomic data and account for complex dependencies among 
genes [16]. When patterns are identified consistently for a given gene set, that gene set 
is hypothesized to play a role in the condition of interest. GSOA-Shiny can handle any 
type of molecular data that can be mapped to available gene-set databases, including 
microarray, RNA-Sequencing, SNV, CNV, protein, and epigenetic data. The GSOA-
Shiny web interface reduces barriers for biologists without bioinformatic experience. It 
includes extensive documentation, an intuitive HTML report, and a novel “hallmark” 
analysis, which summarizes 50 key biological gene sets [17]. This analysis was 
motivated by the large number of gene sets available in the Molecular Signatures 
Database, and the common problem of having too many results, and acts as a base for 
deeper exploration of additional gene sets. 
 
Implementation 
The GSOA-shiny workflow begins by navigating to the GSOA-Shiny webpage 
and uploading the following required data files: (1) data file(s) containing molecular 
measurements, (2) a class file describing which phenotype each sample belongs to, and 
(3) a gene set file where gene symbols or IDs match those in the omic data file(s). Gene 
sets can either be downloaded from the Molecular Signatures Database [18] or 
generated by a user. GSOA-Shiny will mean-center the data and scale to unit variance, 
but we recommend normalizing data using methodologies appropriate for each omic-
profiling technology prior to uploading. Default parameters should be applicable in many 
cases, but the following parameters are customizable: (1) percent of genes to be filtered 






(3) number of cross-validation iterations (more iterations will result in more robust 
results), and (4) the inclusion of a “hallmark” analysis. An in-depth description of each 
data file and parameter can be found under “Instructions for Use” on the GSOA-Shiny 
web interface.  
Once files are uploaded and “Run” is selected, the files will be validated and 
processed. Upon completion, an HTML-based R markdown report will be delivered via 
e-mail. This report includes a list of significant gene sets, a bar chart with the top 20 
ranked gene sets, and a fully searchable and sortable list of all gene sets with 
corresponding AUC, P-value and FDR values. If the “hallmark” analysis parameter was 
chosen, these results will be present on a separate tab titled “hallmark report”. Run times 
vary depending on the number of samples and different types of omic data present. If 
errors occur, an e-mail will be sent with troubleshooting options. We have included 
multiple examples of GSOA-Shiny analyses under the “Examples” tab on the webpage.  
 
Methods 
GSOA-Shiny is a rewrite of its Python-based predecessor, GSOA [16]. GSOA-
Shiny was rewritten almost entirely in R code [19], and is dependent on many R 
packages, including mlr, for machine learning [20], doParallel and foreach, for parallel 
processing [21], GSEABase for handling gene sets [22], rmarkdown, for creating 
customized reports [23], and mailR for sending results [24]. The web interface was 
created using the web application framework, R-Shiny, and was further customized 
using HTML, CSS and JavaScript [25]. GSOA-Shiny is hosted on the web server GSOA-
Shiny, which requires a modern web browser and internet connection. GSOA-Shiny can 
also be run locally by installing GSOA-Shiny from source code, and is platform 
independent. After users upload files to the GSOA website, the data formats are 






analysis takes place. GSOA-Shiny can employ either the Support Vector Machines 
(SVM) [26] or Random Forest [27] classification algorithms. When multiple types of omic 
data are present, the classification algorithm builds a single model that integrates data 
from all omic types, and only considers samples that contain data for all data types. This 
data is then filtered to include only the genes that belong to the gene sets uploaded by 
the user. To begin, the classification algorithms uses k-fold cross validation to predict the 
class of each sample, using only data associated with a specific gene set. This process 
is repeated for n iterations. For each iteration, an area under the receiver operating 
characteristic curve (AUC) value indicates classification accuracy. A high AUC score 
(maximum of 1.0) indicates accurate predictions; 0.5 indicates predictions that are no 
better than random expectation. A p-value is calculated for each gene set as the fraction 
of AUC values from an empirical null distribution that exceed the actual AUC value. For 
multiple-test correction, False Discovery Rate (FDR) values are calculated based on the 
p-values using the BH method. When the analysis is complete, the results are then fed 
through an R script, which generates the final R markdown report, and the results are 
sent to the user via e-mail. We recommend at least 1000 cross-validation iterations to 
prevent FDR values from becoming skewed. 
 
Conclusion 
With the increasing number of publicly available, high-dimensional data sets, 
there is a pressing need for easy-to-use gene set analysis methods capable of handling 
multiomic datasets. GSOA-Shiny meets this demand and is novel because it provides 
advanced methods for integrating multiomic data, accounts for complex dependencies 
within and across data types, provides an easy-to-use, well-documented web interface, 
and an intuitive report. The GSOA-Shiny web interface lowers computational burdens for 






differing operating systems and software versions. GSOA-Shiny is useful for a broad 
spectrum of biological research applications, including identifying dysregulated pathways 
in cancer and other complex diseases. 
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Summary of Findings 
The work presented in this dissertation focuses on analyzing genomic data at the 
pathway level in order to gain a better understanding of tumor behavior and guide the 
use of targeted cancer therapies in cancer. In Chapter 3, the activity of pathways from 
the growth factor receptor network (GFRN) were probed in TCGA breast tumors and cell 
lines using gene expression signatures generated by overexpressing genes from GFRN 
pathways in human primary mammary epithelial cells (HER2, IGF1R, AKT1, EGFR, 
KRAS (G12V), RAF1, BAD). Using the pathway analysis toolkit ASSIGN, two discrete 
GFRN phenotypes were found — one being “survival phenotype”, represented by 
aberrant activation of the HER2, IGF1R, and AKT pathways, and the other being the 
“growth phenotype” represented by aberrant activation of the EGFR, KRAS, RAF1, and 
BAD pathways. These phenotypes described variability in the TCGA gene expression 
data and characterized distinctive patterns in apoptosis evasion and drug response. The 
survival phenotype was more sensitive to drugs inhibiting HER2, PI3K, AKT, and mTOR, 
but more resistant to chemotherapies.  Alternatively, the growth phenotype expressed 
lower levels of BIM and higher levels of MCL-1 proteins, and were more sensitive to 
common chemotherapies and targeted therapies directed at EGFR and MEK.  These 
phenotypes have the potential to pinpoint targetable aberrations for more effective 
breast cancer treatments. 






Gene Set Omic Analysis (GSOA), which identifies multigene pattern differences between 
biological groups. This tool serves as a method to extract biologically relevant patterns 
from large, heterogeneous, multiomic datasets in support of subsequent, hypothesis-
driven experimental studies. GSOA is capable of analyzing any type of omic data, 
including (but not limited to) microarray data, RNA-sequencing data, single-nucleotide 
variant data (SNV), DNA copy-number variation data (CNV), and epigenetic data. 
Machine learning algorithms employed by GSOA account for complex interactions 
among genes, and when patterns are identified consistently for a given gene set, that 
gene set or pathway is hypothesized to play a role in the condition of interest. GSOA 
was validated using simulated data, gene-expression microarray data, RNA-sequencing 
data, CNV data, somatic SNV data, and combinations of these data types. Using GSOA 
in TCGA data, we identified gene sets that showed differences between HER2-positive 
and HER2-negative breast tumors, and between individuals with and without somatic 
mutations in RAS subfamily genes. We also compared uterine serous carcinomas (USC) 
against uterine endometrioid carcinomas (UEC) and identified pathways that may play a 
role in USC treatment, including the MYC pathway. Further analysis of gene expression 
levels and somatic mutations in an independent dataset suggested that key proteins in 
the MYC pathway are upregulated in USC tumors.  
Chapter 5 presented GSOA-Shiny, an easy-to-use, R-shiny-based web 
application for performing gene set analysis on multiomic data. GSOA-Shiny is an 
improved version of our previously published python package GSOA, which required 
bioinformatics experience [1]. The novel GSOA-Shiny web interface makes running 
GSOA straightforward and includes extensive documentation, an intuitive HTML report, 
and a novel “hallmark” analysis, which summarizes 50 key biological gene sets [2]. 






Genomic Resources Are Essential to Oncology 
Identifying the underlying genetic causes of cancer was limited in past 
generations due to technical constraints [3]. However, the emergence of next-generation 
sequencing (NGS) technologies has revolutionized the way we study cancer. We are 
now in a better position than ever to provide patients with highly personalized treatment 
options specific to their malignancies [4, 5]. Data from large-scale single- and 
multiplatform studies such as the Cancer Genome Atlas (TCGA) [6], the International 
Cancer Genome Consortium (ICGC) [7], the Integrative Cancer Biology Program 
(ICBP43) [8], the Cancer Molecular Analysis Project (CMAP) [9], and the Gene 
Expression Omnibus [10] have significantly improved our understanding of cancer. 
These projects have driven an increase in translational research, improved clinical care 
with novel diagnostic, prognostic, and classification systems, and have helped to guide 
physicians in decision-making regarding the consideration of targeted therapies in 
patients with specific molecular alterations [4, 5, 11–13]. The research presented in this 
dissertation would not be possible without these valuable genomic resources.  
The novel GFRN phenotypes discovered in Chapter 3 were discovered by 
analyzing TCGA tumors and ICBP cell line data. The GSOA software, presented in 
Chapter 4, was tested and optimized using TCGA data, and data from GEO was used to 
validate MYC dysregulation in uterine serous carcinoma. Furthermore, large pathway 
databases such as the Molecular Signatures Database [14], Kyoto Encyclopedia of 
Genes and Genomes (KEGG) [15], REACTOME [16], and the Pathway Interaction 
Database [17] have also been extremely important for gene set enrichment analysis 
methods. Gene sets from these databases are essential to running our pathway analysis 
tool, GSOA-shiny. Therefore, large-scale genomic projects and databases are the 






especially beneficial to patients if standard-of-care included depositing genomic data 
from patient tumors into a large database where tumors could be matched against each 
other to better predict response to therapies and better understand rare cancers where 
the genetic causes are still unknown.  
 
Implications 
The work presented in this dissertation contributes to the field of personalized 
medicine, furthering pathway analysis methods, and also aids in bridging the gap 
between molecular biologists and computational biologists. In Chapter 3, we used novel 
pathway-based signatures to characterize the GFRN in breast cancer in an interactive 
way and discovered two discrete GFRN phenotypes with significant differences in cell 
survival mechanisms and drug response in breast cancer. The implications of this study 
are large. First, they contribute to current breast cancer subtyping approaches by adding 
additional biological relevance, as they represent aberrant signaling patterns. Second, 
characterizing individual tumors into these phenotypes may help determine which 
patients will benefit from the targeted treatments identified in cell line experiments. 
However, additional examination is needed before these phenotypes can be used in 
clinical trials for patient selection, including the testing of these phenotypes in patient 
primary tumor cells. Third, newly generated RNA-sequencing signatures for AKT, BAD, 
HER2, EGFR, IGF1R, RAF, and KRAS (G12V) have been validated in cancer cell lines 
and breast cancer patients and have been made publicly available on GEO. These 
signatures can be used by other researchers to probe GFRN signaling in additional 
cancers or other diseases affected by these pathways. Additionally, the pipeline and 
code used for this analysis are fully available at 
https://github.com/mumtahena/GFRN_signatures, and may provide a model for 






The development of GSOA has contributed to the field of gene set analysis in the 
following ways. GSOA can handle almost any type of genomic data which is of 
importance, as combining multiple types of genomic data can lead to discoveries that 
would not happen using one data type in isolation. While some multiomic methods do 
exist, most do not support the use of any omic data, and none have the capability to 
merge multiomic data into a single classifier. There are no other methods, to the best of 
our knowledge, that use machine learning algorithms and multiomic data concurrently for 
gene set analysis. The benefits of using machine learning over traditional statistical 
approaches include the ability to identify multigene patterns and account for up- and 
down-regulated genes. In addition, GSOA can be applied to other data types beyond 
cancer, and can aid in discovering pathways that may underlie other diseases. 
Additionally, the finding of MYC pathway dysregulation in uterine serous carcinoma has 
clinical implications, and provides motivation for more in-depth biological examination 
into this mechanism. 
Lastly, the development of GSOA-Shiny makes a significant contribution to the 
research community. Biologists need bioinformatics skills to run currently available gene 
set analysis tools, or need to take valuable time to learn basic bioinformatics skills to use 
them. This is not realistic for many molecular biologists. This easy-to-use interface has 
the potential to make multiomic gene set analysis more common in the research 
community. In addition, the R shiny framework for building GSOA-Shiny can be used as 
a model for other bioinformaticians who would like to develop their own web applications 
on cloud servers. The code for this is in a full-automated “docker” container, which can 








Limitations and Future Work 
In the GFRN work presented in Chapter 3, we only included signatures for AKT, 
BAD, HER2, EGFR, IGF1R, RAF, KRAS (G12V). However, there are numerous other 
pathways that fed into the GFRN; therefore, to obtain a more complete picture, it would 
be important for future studies to include other pathway nodes such as PI3K, ERK, 
RALA, JNK, MEK, and MEKK1. This analysis was also limited to correlating these 
phenotypes with intrinsic apoptosis and drug response. It would be interesting to probe 
cell lines for other cancer phenotypes such as EMT, autophagy, angiogenesis, and 
immunology. Also, these analyses were conducted in TCGA data and breast cancer cell 
lines; however, it would be important to test these drug response models in patient cells.  
To address this, we are currently developing an assay for which we can test these 
phenotypes in patient cells. This assay will measure the gene expression values for all 
the genes from the GFRN signatures using NanoStringTM technology. We will first 
determine whether patient cells classified into these phenotypes correlate with 
treatments in a large panel of patient cells. If phenotypes can be used to predict drug 
response in patient cells, we can begin a clinical trial where breast cancer patients are 
grouped into the growth and survival phenotypes and disease outcomes and drug 
response can be compared between the two groups. If phenotypes correlate with drug 
response in patients, this assay can be used in the clinic to guide the use of targeted 
therapies. For example, if a patient is not responding to standard chemotherapies, an 
oncologist can order the GFRN phenotype assay, and if a patient falls under the growth 
phenotype, the physician can explore the use of EGFR inhibitors or try another form of 
chemotherapy. If a patient is classified as the survival phenotype, they can be 
considered for HER2 or AKT based therapies or clinical-trails. It would also be 






other cancer types.  
In relation to GSOA and GSOA-Shiny, we have observed situations where the 
FDR values can become unreliable when p-value distributions become skewed. We plan 
to modify the way we calculate our p-values to resolve this issue. Also, the current 
version of GSOA-Shiny only supports the analysis of two biological conditions at one 
time, for example, cancer vs. normal samples. We plan to expand GSOA-Shiny to 
support the analysis of multiple different conditions concurrently. Another limitation is 
that GSOA-Shiny does not provide data on whether a given pathway is up- or 
downregulated, rather it assumes that a pathway is dysregulated, as some genes within 
the pathway may be upregulated while others are downregulated.  Additionally, GSOA-
Shiny run times can be long (up to a few hours) if large multiomic data sets are used.  
Lastly, in the future, it would be of benefit to create a web application for 
ASSIGN, the tool we used in Chapter 3 to estimate pathway activation, and combine it 
with GSOA-Shiny, and have these tools available on one website dedicated to pathway 
analysis. With this, a user could run both methods, and obtain a high-level view of the 
pathways being affected with GSOA-Shiny, and also have a more qualitative 
assessment of which pathways are being activated with ASSIGN. In addition, we plan to 
include all the genes from the GFRN network signatures on the GSOA-Shiny webpage 
so users can also run these signatures with gene set enrichment analysis.  
   
Conclusion 
Overall, this dissertation work identifies two discrete pathway-based growth 
factor receptor network phenotypes in breast cancer that correlate with drug response to 
targeted therapies, and presents a novel multiomic gene set enrichment analysis tool, 
Gene Set Omic Analysis (GSOA) and its novel web application, GSOA-Shiny, for 






personalized oncology, and improves upon methods for the analysis of cancer at the 
pathway level. These findings and methods may help in the future to guide the use of 
targeted therapies in cancer and improve outcomes and survival for patients suffering 
from cancer.  
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